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In vitro and In vivo Characterization of the Infection Efficiency of a Modified
Retrovirus Envelope Glycoprotein for Targeting Gene Transduction
Abstract
Attributes of both the viral glycoprotein and its cellular receptor play key roles in determining the outcome
of infection. This body of work endeavors to illustrate how these two components influence the efficiency
of virus infection in in vitro and in vivo systems with an emphasis on characterizing the transduction
capacity of a novel entry-targeting glycoprotein. In previous work, the Moloney murine leukemia virus
(MLV) envelope glycoprotein (Env) was modified to generate the Sst-RBS glycoprotein. This glycoprotein
was created by replacing the wild type (WT) receptor binding site (RBS), located on the surface subunit
(SU) of the Env, with the somatostatin peptide hormone sequence SST-14. The modifications resulted in
abrogating transduction via the natural MLV receptor and redirecting transduction to a family of five
somatostatin receptors (SSTR). I demonstrate that structural characteristics of the Sst-RBS glycoprotein
and the intracellular fate of the SSTR receptor influence the infection efficiency of pseudotyped MLV and
human immunodeficiency virus type 1 (HIV-1) based lentiviral (LV) particles. Infection and western blot
assays indicate that Sst-RBS retains the structural requirements for mediating levels of transduction that
are comparable to WT and approach within 5-fold that of transduction mediated by vesicular stomatitis
virus (VSV) G protein when each envelope protein is pseudotyped on MLV particles. To address the
contribution of receptor characteristics on infection efficiency, HEK 293 cell lines stably expressing
comparable cell surface levels of SSTR-2, SSTR-3 and SSTR-5; which have natural differences in
intracellular trafficking; were generated. Infection assays revealed that distinctive SSTR subtype-specific
destinations correlated with observable differences in the level of Sst-RBS MLV and LV transduction.
Taken together the results of virus binding, internalization kinetics, pH-neutralizing agents, protease
inhibitor and penetration assays support that SSTR-5 allows a greater level of transduction because
viruses internalized by this subtype are exposed to more permissive intracellular compartments.
Specifically, SSTR-5-associated virions are directed to compartments that are more favorable to cytosolic
penetration of viral cores than the compartment(s) to which virions bound to subtypes 2 and 3 are
directed; possibly due to a more beneficial complement of host cell proteases. These data suggested that
receptor characteristics such as the intracellular fate of internalized virus-receptor complexes exert a
strong influence on the efficiency of infection. Surprisingly, even though the difference in the in vitro
transduction capacity of Sst-RBS and VSV G pseudotyped LV particles was greater than that of the MLV
pseudotypes, the difference did not translate to a reduction in in vivo transduction capacity. A pilot study
examining the feasibility of in vivo transduction demonstrated proof of principle and identified regions of
the murine brain with endogenous surface expression of SSTRs that were as efficiently transduced by SstRBS LV as by VSV G LV.
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Abstract
Attributes of both the viral glycoprotein and its cellular receptor play key roles in
determining the outcome of infection. This body of work endeavors to illustrate how
these two components influence the efficiency of virus infection in in vitro and in vivo
systems with an emphasis on characterizing the transduction capacity of a novel
entry-targeting glycoprotein. In previous work, the Moloney murine leukemia virus (MLV)
envelope glycoprotein (Env) was modified to generate the Sst-RBS glycoprotein. This
glycoprotein was created by replacing the wild type (WT) receptor binding site (RBS),
located on the surface subunit (SU) of the Env, with the somatostatin peptide hormone
sequence SST-14. The modifications resulted in abrogating transduction via the natural
MLV receptor and redirecting transduction to a family of five somatostatin receptors
(SSTR). I demonstrate that structural characteristics of the Sst-RBS glycoprotein and the
intracellular fate of the SSTR receptor influence the infection efficiency of pseudotyped
MLV and human immunodeficiency virus type 1 (HIV-1) based lentiviral (LV) particles.
Infection and western blot assays indicate that Sst-RBS retains the structural
requirements for mediating levels of transduction that are comparable to WT and
approach within 5-fold that of transduction mediated by vesicular stomatitis virus
(VSV) G protein when each envelope protein is pseudotyped on MLV particles. To
address the contribution of receptor characteristics on infection efficiency, HEK 293 cell
lines stably expressing comparable cell surface levels of SSTR-2, SSTR-3 and SSTR-5;
which have natural differences in intracellular trafficking; were generated. Infection
assays revealed that distinctive SSTR subtype-specific destinations correlated with
observable differences in the level of Sst-RBS MLV and LV transduction. Taken together
the results of virus binding, internalization kinetics, pH-neutralizing agents, protease
inhibitor and penetration assays support that SSTR-5 allows a greater level of
transduction because viruses internalized by this subtype are exposed to more
permissive intracellular compartments. Specifically, SSTR-5-associated virions are
directed to compartments that are more favorable to cytosolic penetration of viral cores
than the compartment(s) to which virions bound to subtypes 2 and 3 are directed;
possibly due to a more beneficial complement of host cell proteases. These data
suggested that receptor characteristics such as the intracellular fate of internalized virusreceptor complexes exert a strong influence on the efficiency of infection. Surprisingly,
even though the difference in the in vitro transduction capacity of Sst-RBS and VSV G
pseudotyped LV particles was greater than that of the MLV pseudotypes, the difference
did not translate to a reduction in in vivo transduction capacity. A pilot study examining
the feasibility of in vivo transduction demonstrated proof of principle and identified
regions of the murine brain with endogenous surface expression of SSTRs that were as
efficiently transduced by Sst-RBS LV as by VSV G LV.
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Chapter 1. Introduction

*

Background
Moloney Murine Leukemia Virus
Moloney murine leukemia virus (MLV), a member of the genus gammaretrovirus in
the family Retroviridae; is an enveloped virus containing two copies of a positive-sense,
single-stranded RNA genome. An ecotropic retrovirus (RV), Moloney MLV initiates
infection by binding its host cell receptor mCAT-1 (a mouse cationic amino acid
transporter) to gain entry into host murine cells [1-3]. This interaction is mediated by the
surface subunit (SU) of the MLV envelope protein (Env) which contains the receptor
binding site (RBS). The internalization of MLV-mCAT-1 complexes has been to shown to
occur independently from classical clathrin-mediated endocytosis by a caveolinassociated pathway [4-6]. Following endocytic events, host cell cathepsin proteases
found in the late endosomal compartment cleave the viral Env [7] and trigger
conformational changes in both the SU and transmembrane (TM) domains of Env that
allow the TM fusion peptide to mediate fusion between the virus and host cell
membranes [8]. After the virion core is uncoated and released into the host cytosol a
pre-integration complex (PIC) is formed which includes (among other components) a
double stranded DNA copy of the viral RNA, which has been reverse transcribed by the
viral reverse transcriptase enzyme, and the viral integrase enzyme. The PIC is
transported into the host cell nucleus while the nuclear membrane is dissolved during
mitotic events [9, 10] and the integrated DNA, or provirus, becomes a template for the
generation of new infectious virions by host cell machinery. The entry events of
lentiviruses (LV) such as human immunodeficiency virus type 1 (HIV-1) involve many of
the same requirements as MLV with a notable exception that nuclear import of the PIC
does not rely on host cell mitosis, but rather gains access through nuclear pore
complexes which allow PIC transport across the intact nuclear membrane. It is generally
thought that whereas MLV integration occurs only in actively dividing cells, HIV-1 is
capable of integration in both dividing and non-dividing cells [10]. Consequently, LV is
considered a more appropriate vector for in vivo gene delivery where a majority of target
cells are quiescent (i.e, not actively dividing).
Targeting Gene Delivery
Since the provirus is integrated into the host cell’s chromosome, RVs and LVs are
attractive solutions for investigators interested in targeting delivery of therapeutic genes
to the cell and tissue types most likely to benefit from such therapies. To this end,
numerous attempts at re-directing the MLV Env to new target cells have been published
(for reviews see [11, 12]). The most frequently used insertion sites include the
amino-terminus and the proline-rich region (PRR) of the Moloney MLV SU glycoprotein
*

Adapted with permission. Li, F., B. Y. Ryu, R. L. Krueger, S. A. Heldt and L. M.
Albritton.Targeted entry via somatostatin receptors using a novel modified retrovirus
glycoprotein that delivers genes at levels comparable to those of wild-type viral
glycoproteins. J Virol, 2012. 86(1): 373-381.
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but to date these strategies have remained largely unsuccessful [11-13]. Although the
chimeric virions were generally able to bind their receptors and internalize, membrane
fusion was impaired resulting in little to no transduction in target cells lacking the natural
virus receptor [13-15]. These impairments are more pronounced when ligands are
inserted in the amino-terminus than in the PRR of the SU [14]. Additionally, altering
critical residues in the amino-terminus blocks infection at a hemi-fusion point [8]. While
simple RVs , such as MLV, have found specific uses as vectors for delivering genes in
cell culture and ex vivo therapies (removing cells from the body and transducing them
before re-implantation) targeting hematopoietic stem cells [13] they have limited use in
vivo, however. This is mainly due to the restrictions imposed on them from cell division
requirements during provirus integration and a capacity to induce oncogenesis through
unregulated integration events [16]. Strategies utilizing other virus species have been
developed and involve antibody-based strategies using single-chain fragment variable
(scFv) fused to the c-terminus of the measles virus hemagglutinin H protein [17-19] or
the immunoglobulin Fc-binding ZZ domain from Staphylococcus aureus protein A into
the E1 glycoprotein from Sindbis virus [20]. The in vivo potential for these systems is
also limited because low levels of viral membrane incorporated glycoproteins occurred
due to aggregation of the scFv leading to incorrect assembly [21] as well as unstable
interactions [20] and rapid vector inactivation by compliment [22]. Lentiviral based
strategies might be more effective for in vivo targeting efforts because they are capable
of transducing terminally differentiated cells which may no longer be actively dividing.
Lentivirus vectors pseudotyped with the glycoprotein from amphotropic MLV [23] and the
vesicular stomatitis virus (VSV) G protein [24], both of which are capable of infecting
nearly every mammalian cell type, have been widely used for gene delivery [13].
However, the broad host ranges of these two proteins do not reflect true targeted
delivery to specific cell types.
Sst-RBS: A Modified MLV Envelope Glycoprotein
A new targeting strategy was devised by previous researchers in this laboratory
based on structural similarities of the Moloney MLV RBS and a small peptide hormone,
somatostatin 14 (SST-14) [25]. The resulting modified Env glycoprotein, Sst-RBS, was
created by replacing the wild type (WT) RBS (residues C73 to C86 of Moloney MLV)
with the SST-14 sequence and short amino- and carboxy-peptide linker sequences
(Figure 1-1) [25]. The linker sequences were designed to form rigid structural turns
directing the SST-14 sequence up and away from the SU, in a manner similar to the
published structure of the Friend strain of MLV [26]. The modifications that created SstRBS resulted in a switch from the use of mCAT-1 to somatostatin receptors (SSTR) [25],
a family of multi-membrane spanning G protein-coupled receptors (GPCR). These
receptors are not entry receptors for any known virus and ordinarily recognize SST-14,
related ligands and peptide mimetics. Replacing the WT RBS with a ligand that binds a
human transmembrane receptor has several advantages. First, it has the greatest
chance of maintaining the virus’s natural mechanism of entry, except of course, that
infection would occur via the new receptor. Second, it reduces issues related to structure
that affect protein folding and virion assembly. Lastly, it abolishes the natural murine
host specificity of the virus generating clear evidence that the virus has been retargeted.
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Figure 1-1. Schematic of the Sst-RBS and wild-type glycoprotein
Schematic representation of the surface subunit of wild type ecotropic Moloney (WT,
Top) and Sst-RBS (Bottom) envelope glycoproteins with the locations of the receptor
binding site (RBS) in WT and the peptide sequence YASAGCKNFFWKTFTSCAYTAS
containing the SST-14 ligand (underlined) flanked by short peptide linkers. RBD:
Receptor Binding Domain, PRR: Proline Rich Region, CTD: Carboxy-Terminal Domain.
Somatostatin and Its Receptor Family
SST-14 is a small peptide hormone that primarily exerts regulatory effects on cells
of the endocrine and exocrine systems in mammals and fish. Notably, it inhibits the
release of other hormones such as growth hormone and somatotropin, functions as a
neurotransmitter, and has anti-proliferative and cell differentiation actions. Two
biologically active forms are produced by preproprotein cleavage: a 14 (SST-14) and a
28 (SST-28) amino acid peptide. The SST-14 cleavage product is most commonly used
as a receptor agonist; both ligands form a hairpin loop structure stabilized by an internal
disulfide bond [27]. The sequence FWKT, located at the center of the hairpin, is required
for functional binding to a family of five multi-membrane spanning GPCRs [28]. The five
SSTR subtypes: SSTR-1, SSTR-2 (A and B), SSTR-3, SSTR-4, and SSTR-5 can be
classified into two groups based on structural and pharmacological properties. Group 1
includes SSTR-2 (A and B), SSTR-3 and SSTR-5 whereas SSTR-1 and SSTR-4 belong
to Group 2. Group 1, but not Group 2, receptors are capable of binding important SST
analogues such as octreotide [29] and are more efficiently internalized after agonist
exposure [30]. Subsets of SSTR monomers, homo- and heterodimers are naturally
expressed in many cell types; however, the SSTR-2A isoform is the most widely
distributed [29]. Additionally, SSTRs may heterodimerize with other receptors such a
dopamine type 2 [31]; epidermal growth factor receptor, ErbB [32] and the mu-opioid
receptor, MOR1 [33]. Surface expression of SSTRs is abundant in the brain;
gastrointestinal tract; exo- and endocrine pancreas and pituitary and have been
identified in multiple tumor types and cell lines [27, 28].
Despite the gene for each SSTR subtype being located on separate chromosomes,
the SSTRs display remarkable sequence homology. There is 39-57% homology
between the five subtypes with most variability occurring in the carboxy-terminal
cytoplasmic tails and a notable conserved motif located in transmembrane domain VII.
The SSTR also show 82-99% homology across mammalian species [27]. As would be
expected based on such similar homology, SSTR subtypes bind SST-14 with
comparable nanomolar affinities [27, 29]; however, binding affinities between the SSTRs
and other ligands do vary. For instance, while SSTR-2 and SSTR-3 bind SST-28 with
similar affinities to SST-14, SSTR-5 has a higher affinity for SST-28 [27, 30].
Furthermore, octreotide, a synthetic octapeptide that mimics the agonist effects of the
natural SST ligand, binds SSTR-2 with a higher affinity than both SSTR-3 and SSTR-5
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[27, 34]. In addition to the range of ligand-receptor affinities there is also evidence that
various ligands may change the degree of signaling or endocytosis based on different
conformations of the ligand-receptor complex [34]. As an example, the non-peptide
ligand L-779,976 binds to SSTR-2 with the same affinity as SST-14, but is 10 times more
potent at inhibiting cAMP production (a common measure of SSTR signaling) and yet
could only produce 70% of SST-induced receptor internalization [35]. These differences
might be attributable to a relatively large,[27] putative ligand binding pocket which is
thought to span multiple residues across transmembrane domains III-VII [29].
Intracellular Trafficking of Somatostatin Receptors
A common feature of GPCRs is agonist induced receptor desensitization. Agonist
binding stimulates GPCR signaling which it is regulated, in part, by phosphorylation of
intracellular receptor domains. Receptor phosphorylation also recruits β-arrestins.
Depending on the class of GPCR, β-arrestin may not be stably associated with the
desensitized receptor complex, thus while the desensitization process generally (but not
always) involves receptor internalization, β-arrestin might not be internalized with the
complex. Internalization of the GPCR is followed by receptor degradation or
resensitization/recycling. These actions allow the cells to correspondingly either
down-regulate or preserve the amount of unbound receptors on the cell surface during
prolonged agonist exposure. In some cases, mobilization of intracellular stores quickly
up-regulates surface receptors. The pattern of phosphorylation and β-arrestin
recruitment determines the extent of SSTR internalization, resensitization and recycling;
and depends, to a large degree, on the presence and location of clusters of Ser and Thr
phosphate acceptor sites [34]. Because the carboxy-terminal cytoplasmic tails differ
among SSTR subtypes 2, 3 and 5 with respect to the amount and position of putative
phosphorylation sites and β-arrestin recruitment, so does their method of desensitization
[30, 36]. As a result, the intracellular fates of the ligand-receptor complexes are also
distinct (Figure 1-2).
In the absence of agonist, SSTR-2 and SSTR-3 are almost entirely localized at the
plasma membrane, but a large amount of SSTR-5 can be found in intracellular pools in
certain cell types [34, 37]. After agonist exposure, phosphorylation of clusters of
acceptor sites occurs in SSTR-2 and SSTR-3, but these clusters are absent in the
cytoplasmic tail of SSTR-5. Stable β-arrestin complexes are only associated with
SSTR-2 and their formation is dependent on G protein-receptor kinase (GRK)-mediated
phosphorylation. Conversely, β-arrestin is only transiently associated with SSTR-3 and
SSTR-5. SSTR-2 and SSTR-3 are rapidly internalized in response to β-arrestin
recruitment, and at early time points both are co-localized with transferrin; a commonly
used early endosome marker [36]. SSTR-2 is recycled back to the plasma membrane
through the trans-golgi network (TGN) [30] without any detectable loss of the receptor
[36]. Various SST analogues are reported to have differing fates when internalized with
SSTR-2: SST-14 is degraded by cellular peptidases located in the early endosome and
the cleavage products are subsequently released. Endothelin-converting enzyme-1
(ECE-1) has been implicated; although treatment with the ECE-1 inhibitor SM-19712
only partially inhibits SST-14 degradation; indicating other proteases may also be
responsible. Octreotide, however, is released unaltered from cells [38]. After SST-14
induced endocytosis of SSTR-3, only a small amount of the receptor is redistributed
back to the plasma membrane. Most SSTR-3 loses transferrin association as the
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Figure 1-2. Somatostatin receptor subtypes have different intracellular fates
Following SST-14 ligand-induced receptor internalization, each SSTR subtype is
trafficked to acidified vesicles. During the process of desensitization, the ligand is
proteolytically cleaved from SSTR-2 (blue), the receptor is returned to the plasma
membrane and free ligand is released through the recycling pathway. SST-14 bound to
SSTR-3 (green) is directed to the lysosomal compartment and both ligand and receptor
are degraded. The intracellular fate of SSTR-5 (red) is unclear, but it may also be
recycled back to the cell surface.
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process progresses, undergoes ubiquitin-dependent lysosomal degradation and is
consequently down-regulated in response to prolonged SST-14 exposure [36]. In rat
insulinoma (RIN) cells expressing SSTR-3, SST-14 colocalizes with the lysosomal
protease cathepsin D, is degraded in a low pH dependent manner and products are
released from the cell. In contrast, octreotide is released back into the supernatant intact
and SSTR-3 is continuously recycled [39]. When SST-14 is internalized with SSTR-5 in
COS-7 cells, the level of surface SSTR-5 is quickly replenished through a combination of
mobilization from intracellular pools and receptor recycling while internalized ligand is
directed to an unidentified perinuclear compartment, possibly lysosomes [37]. From the
wide range of literature on the subject, it is clear that species, ligand and cell-type
specific intracellular events make desensitization an extremely dynamic process.
Statement of Purpose
Several approaches to modifying viral glycoproteins to address the idea of targeting
gene delivery have been developed (reviewed in [11-13]). To date, the main approach
has been to insert ligands and proteins into various regions of virus Env proteins in order
to redirect the virus to new host cell receptors. This strategy has been ineffective
because these chimeras remain incapable of triggering the correct conformation
changes in Env that allow membrane fusion. Creating effective therapeutic viral vectors
entails generating a virus with the greatest potential for transduction and it is clear that
the largest barrier to this requirement has been membrane fusion. Attributes of both the
viral glycoprotein and its cellular receptor play key roles in mediating events such as
membrane fusion capacity and influence the efficiency of infection. The modifications
employed during development of the Sst-RBS glycoprotein retain the potential for
membrane fusion; however, the question remains whether Sst-RBS is useful for
targeting gene delivery in vivo. The goal of this dissertation is to characterize the
infection efficiency of the Sst-RBS glycoprotein and demonstrate its potential for
targeting in vivo gene delivery.
•

The objective of Chapter 3 is to demonstrate that characteristics of the Sst-RBS
glycoprotein influence infection efficiency by evaluating the structural
requirements of the SST-14 replacement region. An additional goal is to
determine the capacity for in vitro transduction by Sst-RBS compared to WT and
VSV G envelope proteins in an effort to develop a high capacity LV vector
suitable for targeting in vivo gene delivery.

•

The objective of Chapter 4 is to identify characteristics of the cellular receptor
that influence infection. By investigating how intracellular events following
receptor endocytosis affect the outcome of infection I hope to assess if
specifically targeting receptors with certain intracellular pathways should be
considered in the development of future targeting vectors.

•

The objective of Chapter 5 is to demonstrate proof of principle for in vivo
transduction and identify regions of the murine brain with endogenous surface
expression of SSTRs that are susceptible to infection by the Sst-RBS
glycoprotein.
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Chapter 2. Methods
Cell Lines
Cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) high glucose
supplemented with 8% donor calf serum (Invitrogen) for mouse NIH 3T3 and HEK293
(293) cells, or 8% fetal bovine serum (FBS, Invitrogen) plus 250 µg/ml G418 (BioGold)
for the H1BAG, 293/SSTR-2, -3, -5 and 293FT cells.
293/SSTR-expressing Cell Lines
The 293/SSTR-5 cell line was generated using plasmid Alpha+12CA5/SSTR5
(Affymax, Palo Alto, CA) and sorted as previously described to obtain a population
expressing cell surface SSTR-5 at levels comparable to that of endogenous mCAT-1 on
NIH 3T3 cells [25]. The 293/SSTR-2 and -3 cell populations were generated similarly by
transfection of 293 cells with expression plasmids Alpha+12CA5/SSTR2 or
Alpha+12CA5/SSTR3 (Affymax) encoding amino-terminal HA epitope tagged human
SSTR subtypes 2 and 3, respectively, linked to a G418 resistance gene cassette, and
stable transfectants selected by culture in 1 mg/ml G418 for four weeks followed by
Fluorescence activated cell sorting (FACS) using mouse anti-HA monoclonal antibody
HA.11 (Covance, 1:200 dilution) and goat anti-mouse conjugated to Alexa488 (Molecular
Probes, 1:400 dilution) to obtain populations whose surface expression of SSTR-2 or -3
was comparable to that of the 293/SSTR-5 cell line.
HIBAG Producer Cell Line
The H1BAG cells used to produce pseudotyped MLV particles has been described
previously [25]. Briefly, HEK293 cells were transfected with the BAG genome [40] and
single-cell cloned to obtain a population of cells stably expressing a murine leukemia
virus intact long-terminal-repeat controlled lacZ-transducing retroviral genome.
Plasmid Construction
Sst-RBS and Flexible Flanking Sequence Modified Glycoproteins
The following primer sequences were created to generate intermediate plasmids
pcDNA-Sst-RBS and pcDNA-Sst-RBS-2 from pcDNA-DelRBS-Opti (a plasmid encoding
a codon optimized version of the MLV env in which the RBS has been deleted) using
ExSite Mutagenesis technology (Stratagene) and PrimeStar HS DNA Polymerase
(Takara); DelRBS-Opti Return Primer: 5’ PHOS G TCC TGG AGG ACT ACT GAA TG
3’, DelRBS-Opti SstMut1 Primer: 5’ PHOS CG CCT TAC GCG TCC GCT GGC TGC
AAG AAT TTC TTC TGG AAG ACC TTC ACT AGT TGC GCG TAT ACC GCT AGT
GAG GAG CCA CTG AC 3’, and DelRBS-Opti SstMut2 Primer: 5’ PHOS CT CCT AGC
GGC GGT GGA GGA GCT GGC TGC AAG AAT TTC TTC TGG AAG ACC TTC ACT
AGT TGC AGC GGT GGA GGA GGC GAG GAG CCA CTG ACA TCT TTG 3’. The
unique restriction sites PmlI and BspEI in pcDNA-DelRBS-Opti and the SpeI site in
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Sst-RBS were used to recombine the 5’ and 3’ flanking sequences to generate two more
plasmids; pcDNA-Sst-RBS-3 and pcDNA-Sst-RBS-4. The restriction sites PmlI and
BspEI were again used to lift the four Sst-RBS sequences out of the pcDNA-DelRBSOpti intermediate backbone and insert them into the TS45 expression plasmid
generating Sst-RBS, Sst-RBS-2, Sst-RBS-3 and Sst-RBS-4.
FEGW
The expression plasmid encoding an HIV-based self-inactivating (SIN) LV genome
encoding green fluorescent protein (GFP) under control of the human elongation factor
1-alpha (hEF1α) was created by removing the human Ubiquitin C promoter (hUBC) from
FUGW (Addgene [41]) and replacing it with hEF1α from pEF1/Myc-His A (Invitrogen)
using In-Fusion (Clontech, manufacturer’s instructions) between the PacI and BamHI
restriction sites with the following primers. EF1a-FUGW For: TGA TTA TTG ACT AGG
CTT TTG CAA AAA GCT TTG CAA AGA TGG ATA AAG TTT TAA ACA GAG AGG AAT
CTT TGC AGC TAA TGG ACC TTC TAG GTC TTG AAA GGA GTG GG and Ef1aFUGW Rev: GGA ATT AGC TTG GTA CTA ATA CGA CTC ACT ATA GGG AGA CCC
AAG CTG GCT AGG TAA GCT TGG TAC CGA GCT CGG ATC CAC TAG TCC AGT
GTG GTG GAA TTC TGC AGA TAT CCA GCA CAG TGG CGG CCG CTC GAG TCT
AGA GGG CCC TT.
Pseudovirus Production
MLV pseudovirions transducing β-galactosidase were produced by calcium
phosphate co-precipitation transfection of H1BAG cells using plasmids encoding the
Moloney MLV gag and pol genes (35 µg) and either the wild type (WT) Moloney or
Sst-RBS env gene (18 µg) or a vesicular stomatitis virus (VSV) G protein cDNA (4 µg) in
a T-75 flask. The precipitant was removed and fresh growth media added after 16 hours,
supernatants collected 24 and 48 hours later, and cell debris removed by 0.45 µM
syringe filter (Millipore). Viral supernatants were generally used fresh (no freeze-thaw),
further concentrated as indicated in the experimental procedure or stored at -80 °C for
later use.
Sst-RBS coated lentiviral pseudovirions transducing enhanced GFP were produced
by Lipofectamine 2000 (Invitrogen, manufacturer’s instructions) transfection of 293FT
cells (Invitrogen) with plasmids FEGW (3.75 µg) pCMVd8.2dvpr (Addgene, 11 µg)
encoding the gag, pol and rev genes from HIV-1 and the Sst-RBS env gene (8.4 µg) in a
T-75 flask. The VSV G LV was produced by Lipofectamine 2000 transfection of 293FT
cells with FEGW or FUGW (3.75 µg) and the Virapower Lentivirus plasmid mix
(Invitrogen, 11.25 µg) in a T-75 flask. The transfection mix was removed and fresh
growth media without phenol red added after 16 hours, supernatants collected 24 and 48
hours later, and cell debris removed by 0.45 µM syringe filter. Supernatants were
concentrated by ultracentrifugation at 18,000 rpm for 3 hours at 4 °C (Beckman Coulter
Optima L-90K Ultracentrifuge SW28 rotor) then resuspended in ice cold phosphate
buffered saline (PBS) at 100-fold the original volume. Concentrated lentiviral stocks were
used fresh (no freeze-thaw) or stored at -80 °C for later use.
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Lentivirus transducing mKate2, firefly luciferase and puromycin resistance were
produced by the University of Tennessee Health Science Center Viral Vector Core.
Infection Assays
End-point dilution titrations of MLV pseudovirions were performed by exposing host
cells seeded (at approximately 25% confluence to allow room for cell division necessary
for MLV provirus integration) in quadruplicate on 48-well plates to ten-fold serial dilutions
of virus supernatant in the presence of 10 µg/ml polybrene (Sigma) using spinoculation
(centrifugation at 2250 rpm in a Jouan CR 412 for 30 minutes at 24 °C). Forty-eight
hours later, the cells were fixed with 0.5% gluteraldehyde, stained with 5-bromo-4chloro-3-indolyl-β-D-galactopyranoside (X-Gal) and transduction was quantified by
scoring the lacZ positive foci using light microscopy.
Titration of puromycin resistance-transducing lentiviral stocks was performed
similarly except that 36 hours after virus exposure, cells were fed with medium
containing 1 µg/ml puromycin and the drug was maintained for two weeks at which time
surviving drug-resistance colonies were fixed and stained for enumeration using 1% v/v
crystal violet (Sigma) in Ethanol. For GFP-transducing LVs, host cells were seeded (at
approximately 40% confluence) in a 24-well plate and exposed to 300 µl of 100X
concentrated lentiviral (100,000 NMWL Centricon-Plus Millipore) stock resuspended at
5X for Sst-RBS or 1x10-2 for VSV G pseudotypes in the presence of 10 µg/ml polybrene.
Cells were spinoculated, and split into 6-well dishes 16 hours later. Infection was
quantified by flow cytometry for the presence of GFP at 72 hours post infection (hpi).
SDS PAGE Western Blot Analysis
Virus supernatants were prepared for analysis by concentrating 9 ml by ultracentrifugation at 30,000 rpm for 90 minutes at 4 ºC and resuspending the pellet in 30 µl
of ice cold PBS. Pre-cast 4-20% Sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS PAGE) gels (Pierce) were loaded with 10 µl pellet in 2X gel
loading dye boiled at 95 ºC for 10 minutes or 5 µl protein marker (Bio-Rad). The gel was
electrophoresed for 15 minutes at 80 V then 30 minutes at 110 V. Protein was
transferred to a nitrocellulose membrane overnight at 30 V. The membrane was probed
with goat anti-Rauscher SU (Quality Biotech, 1:100 dilution) a primary antibody
recognizing the MLV SU protein for 1 hour, horseradish peroxidase conjugated
secondary antibody for 1 hour (Sigma, 1:5,000 dilution) and visualized with
chemiluminescent substrate (Pierce). The membrane was stripped (Bio-Rad) and reprobed using goat anti-Rauscher CA (1:10,000 dilution) a primary antibody recognizing
the MLV capsid protein as a loading control.
Virus Binding
Equilbrium binding assays were performed as previously described [42]. Briefly,
Sst-RBS MLV was concentrated 20X by low speed centrifugation using Centricon-100
devices (Millipore) then incubated with approximately 1x106 non-transfected 293 or
293/SSTR-2, -3, or -5 cells for 30 minutes at 37 °C to allow maximal virus particle
binding. After washing out unbound virus with PBS the cells were incubated for 1 hour at
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4 °C with goat anti-Rauscher SU (Quality Biotech, 1:100 dilution) cleared by
pre-incubation with 293 cells and for 30 minutes with mouse anti-goat Alexa-488
(Molecular Probes, 1:400 dilution). Finally, 2 µg of propidium iodide (Sigma) added to
gate out membrane compromised cells. Flow cytometry of at least 10,000 events was
performed and the population of propidium iodide -negative, Alexa-488-positive cells
was analyzed. The fold binding of Sst-RBS MLV to each cell line was determined by
comparing the mean fluorescent intensity (MFI) of each SSTR-expressing cell line
exposed to Sst-RBS MLV to the MFI of non-exposed populations (this normalizes for
background fluorescence).
Receptor Internalization
Receptor internalization studies were performed similarly to the equilibrium virus
binding assay but with the following exceptions: incubation with 1 µM of synthetic
SST-14 peptide (Sigma, S-9129) for 30 minutes followed by incubation for 1 hour at 4 °C
with mouse anti-HA.11 monoclonal antibody (Covance, 1:200 dilution) and goat
anti-mouse conjugated to Alexa488 (Molecular Probes, 1:400 dilution).
Kinetics of Virus Internalization
To determine the internalization kinetics viruses were spinoculated onto host cells
seeded in quadruplicate wells of 48-well plates by centrifugation at 2250 rpm (Jouan CR
412) for 30 minutes at 4 °C in the presence of 10 µg/ml polybrene, after which
non-internalized virions were inactivated by a pH 3.0 citrate buffer wash immediately (0
hour time point) or at various times after shifting the cells to 37 °C as previously
described [43]. Infection was allowed to continue for 48 hours prior to fixation with 0.5%
gluteraldehyde and stained with X-Gal. β-galactosidase activity was quantified using the
Romanizer software package ((http://cfar.ucsd.edu/romanizer/) as described by Day and
coworkers [44] except that the digital images of whole fixed and stained wells were
captured using a D50 digital camera (Nikon) mounted on a SZ-PT microscope
(Olympus) by Tim Higgins in the Department of Microbiology, Immunology and
Biochemistry. In a pilot experiment, infected 293/SSTR-5 and NIH 3T3 cells were too
numerous to count accurately either by visual scoring using light microscopy or using the
Romanizer software so in the experiments reported here these cell lines were
spinoculated with 100-fold dilutions of the Sst-RBS or WT MLV, while the 293 and
293/SSTR-2 and -3 host cells were spinoculated with neat Sst-RBS MLV stocks. The
relative rate of virus internalization was calculated by non-linear regression analysis
using GraphPad Prism software and the amount of time to reach 50% infection
extrapolated from each equation.
Drug and Inhibitor Studies
Stock solutions were prepared as follows: 500 mM methyl-β-cyclodextrin (Sigma,
C4555), 30 mM chloroquine diphosphate salt (Sigma), 5 mg/ml leupeptin hemisulfate
(Peptides International) in H2O, 3 mM monensin in EtOH (ready to use as GolgiStop,
BD) and 10 mM CA074 Me (Peptides International), 10 mM nocodazole (Sigma), 20 mM
bafilomycin A1 (Sigma) in DMSO. Cells seeded in quadruplicate wells on 96-well plates
were pretreated with medium containing the indicated concentration of each compound
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or vehicle for 30 min (methyl-β-cyclodextrin; bafilomycin A1, chloroquine, monensin and
CA074 Me) or 1 hour (leupeptin and nocodazole) at 37 °C, then virus was spinoculated
as described above except that virus plus drug or vehicle was maintained for 3 hours
after spinoculation, then unbound virus and drugs were removed by two gentle washes
with culture medium. For cells treated with methyl-β-cyclodextrin, each well was rinsed
twice with Optimem I serum-free medium and methyl-β-cyclodextrin or vehicle was also
diluted in Optimem I prior to its addition to adherent cells. At 48 hpi, cells were fixed and
stained with X-Gal and transduction was scored using the Romanizer software to
analyze digital images of entire wells. In order to obtain levels of infection that could be
accurately quantified, 1:20 dilutions of control VSV G MLV were used on all cell lines
and the same dilutions of Sst-RBS and WT MLV on 293/SSTR-5 and NIH 3T3 cells,
respectively. The amount of infection in the vehicle-only control wells was taken as
100% infection and the percent infection of each cell line was calculated for each
experiment individually to determine the mean percent infection in the quadruplicate
wells.
Quantitative Real-time PCR Analysis
The quantitative real-time PCR assays were performed as previously described by
Gao and colleagues [45] with the following modifications. New primer sets were
developed for the MSS and lacZ of the recombinant MLV genome, and for human and
murine β-actin control amplicons. Three-fold concentrated Sst-RBS or WT MLV
pseudovirions, or mock (no virus) were spinoculated onto the cells by centrifugation at
2250 rpm (Jouan CR 412) for 30 min at 4 °C in the presence of 10 µg/ml polybrene, then
unbound virus was washed away and the cells fed fresh medium. Whole cell DNA was
isolated immediately with no temperature shift for the zero time point, and replicate
samples were also shifted to 37 °C for 6 hours prior to DNA isolation using a DNeasy
Blood and Tissue Kit (Qiagen). The whole cell DNA was used directly as template for
analysis by quantitative real-time PCR using the Light Cycler 480 instrument (Roche)
and the following primer and probe sets: Minus Strand Strong Stop (MSS), forward
(MSS82-F) 5’-ACT TGT GGT CTC GCT GTT CC-3’, reverse (MSS82-R) 5’-CGC TGA
CGG GTA GTC AAT C-3’ and Universal Probe #82 (Roche); LacZ gene, forward
(LacZ74-F) 5’-GAC CGC ATG GTC AGA AGC-3’, reverse (LacZ74-R) 5’-CTG AGG TTT
TCC GCC AGA C-3’ and Universal Probe #74; Human β-actin gene, forward (hBAct60F) 5’-GCC GTG TTC TTT GCA CTT TC-3’, reverse (hBAct60-R) 5’-GCA GAG ATG CAC
CAT GTC AC-3’ and Universal Probe #60; murine β-actin gene: forward (mBAct29-F)
5’-CAC GCC CTT TCT CAA TTG TC-3’, reverse (mBAct29-R) 5’-CCA AGG GAG ACT
CAG CTC ATA-3’ and Universal Probe #29. MSS and LacZ gene amplification were
normalized to the values obtained for β-actin amplification for each respective host cell
line. The relative amount of cell-associated virus was calculated by comparing the MSS
amplification signal at the 6 hour time point for each SSTR-expressing cell lines to the
level in the parent 293 cells using the delta delta Ct calculation. Values were then
expressed as the relative fold increase over the 293 value. To determine the relative
amount of penetrated virus the delta delta Ct calculation was used to calculate the
relative level of MSS signal at the zero and 6 hour time points with respect to the level of
LacZ gene signal in each cell line, and then expressed as the fold increase over the zero
hour time point.
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In Vivo Experiments
Animals
The animal protocol used in this study has been approved by the Institutional Animal
Care and Use Committee at the University of Tennessee Health Science Center
(UTHSC). Nine to twelve week old C57BL/6J mice were purchased from Charles River
Laboratories (Wilmington, MA, USA). Mice were allowed free access to food and water.
Intracranial Microinjection
Bilateral, stereotaxic microinjections were performed on anesthetized mice using
the following protocol. Nine to twelve week old C57BL/6 mice skulls were shaved and
incision site prepped with betadine then mice were mounted into a stereotaxic
apparatus. Small holes were drilled in the skull bone directly above the injection sites
and a 30-gauge Hamilton microsyringe lowered to the following coordinates from
bregma: Caudate Putamen: AP= -0.5, ML= ±2.0, DV=-4.0; Subthalamic Nucleus:
AP= -1.9, ML= ±1.5, DV= -5.2. After the microsyringe had been lowered to the
coordinates, it was left in place for 10 minutes before and after administration of lentiviral
injections. A total volume of 2 µl concentrated Sst-RBS or a 100-fold dilution of
concentrated VSV G pseudotyped lentiviral vectors transducing a SIN HIV-1 based
genome encoding the marker gene mKate2 under the hUbC promoter were injected into
the left hemispheres of 4 mice at a rate of 0.7 µl/min. The same virus preparations were
also injected into the contralateral hemisphere of each mouse immediately after injection
with 0.5 µl of 100 µM SST-14 peptide. After the injection procedure was complete, the
skull incision was closed and mice were allowed to recover in a BSL-2 housing facility.
Three days post infection the mice were sacrificed, organs perfused with PBS and the
brain tissue recovered for analysis.
Tissue Section Staining
Brain tissue from injected and control mice were fixed in 4% paraformaldehyde then
sunk in a 25% sucrose phosphate buffer solution and flash frozen in Isopentane. A
microtome was use to slice 20 µm sections which were placed on clean, glass slides.
Slides were soaked in 1X PBS to remove the sucrose solution from the sections just
prior to staining to allow antibodies proper access to epitopes. Sections were blocked for
20 minutes with 3% BSA/ 0.8% Triton X-100/ 0.2M PBS prior to co-incubation with
monoclonal rabbit anti-SSTR-2 (Epitomics, 1:1000 dilution) and monoclonal mouse
anti-neuronal nuclear membrane protein (NeuN) (Millipore, 1:2000 dilution) diluted in
blocking buffer overnight followed by incubation with Alexa-488, Alexa-594 or Alexa-647
conjugated secondary antibodies (Molecular Probes, 1:1000 dilution) for 2 hours.
Hoechst nuclear stain (100 µM) was added to stained sections for 20 minutes prior to
mounting in 90% glycerol/PBS and imaged on a Zeiss Deconvolution microscope or in
FluorSave (Calbiochem) and imaged using an Aperio Scanscope.
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Transduction Zone Measurements
The mean transduction area (TA) of multiple sections from three mice injected with
2 µl of either the Sst-RBS or VSV G pseudotyped LV vectors was quantified using
ImageJ software (National Institutes of Health, v1.46r). Transduction of mKate2 was
analyzed for each coronal section. These values were then used to calculate a mean TA
for individual mice and an overall mean TA for each lentiviral vector.
The mean transduction zone (TZ) of multiple sections from three mice injected with
2 µl of either the Sst-RBS or VSV G pseudotyped LV vectors, in the presence or
absence of 100 µM SST-14, was quantified by measuring the height (h) and width (w) of
the core and maximum TZ using ImageScope software (Aperio, v11.2.0.780) and
calculating the elliptical area using the formula a=πhw/4. The core TZ was defined as the
area with the highest concentration of mKate2 expression and the maximum TZ as the
largest overall area of mKate2 expression. Mean TZ areas were calculated for individual
mice which were then used to calculate an overall mean TZ area for each lentiviral
vector.
Statistical Analysis
Descriptive statistics for all data were performed using Prism GraphPad Software
v4.0.
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Chapter 3. Targeted Entry via Somatostatin Receptors Using a Novel Modified
Retrovirus Glycoprotein that Delivers Genes at Levels Comparable to Those of
Wild-Type Viral Glycoproteins†
Introduction
Retro- and lentivirus vectors are commonly used as vehicles for marker and
therapeutic gene delivery because they naturally integrate a copy of their genomic
material into the host chromosome during infection. Generally, these vectors use the
Env glycoprotein from amphotropic MLV or the VSV G protein. Unfortunately, the broad
tropism of these glycoproteins mediates gene transduction of most cells after in vivo
injection, resulting in the need for a far greater vector inoculum than would be required if
entry could be restricted to the target cells or tissues capable of benefiting from
therapeutic gene delivery. This is one of the most significant challenges to targeted in
vivo gene delivery [13].
Addressing the need for targeted delivery in vivo, a number of approaches based on
RV and LV particles have been reported (for reviews see [11, 12]). Placing glycoproteins
modified with ligand insertions directed to cellular receptors onto virus particles
(pseudotyping) is a common strategy. Although these chimeric virions were generally
able to bind their receptors and internalize, membrane fusion was impaired resulting
very low levels of transduction [13-15]. Since Env conformational changes are normally
activated by interactions of the Env RBS with its cellular receptor to initiate membrane
fusion, a new strategy was proposed to replace the MLV RBS with a peptide ligand.
Other researchers in this laboratory demonstrated that a chimeric MLV Env
glycoprotein based on this design, Sst-RBS (Figure 1-1), was capable of infecting 293
cells expressing the SSTR-2 receptor and no longer used its natural receptor, mCAT-1.
This infection was found to be SSTR-specific as evidenced by dose-dependent inhibition
of infection using exogenous SST-14 peptide [25]. The strategy used in designing the
Sst-RBS glycoprotein should mimic natural virus-receptor interactions as the Sst-RBS
Env binds to its target receptor and be capable of inducing membrane fusion, thus
allowing targeted transduction. It was demonstrated that an important positional
requirement for the glycoprotein was satisfied by placing the SST-14 sequence at the
RBS. In this chapter I report that an additional glycoprotein characteristic, conferred by
specific structural properties of the Sst-RBS replacement sequence, influences infection.
Additionally, the transduction capacity of pseudovirions bearing the Sst-RBS
glycoprotein was comparable to the efficiency of natural retroviral glycoproteins and
approached that of VSV G; establishing Sst-RBS as a suitable candidate for in vivo gene
transfer.

†

Adapted with permission. Li, F., B. Y. Ryu, R. L. Krueger, S. A. Heldt and L. M.
Albritton.Targeted entry via somatostatin receptors using a novel modified retrovirus
glycoprotein that delivers genes at levels comparable to those of wild-type viral
glycoproteins. J Virol, 2012. 86(1): 373-381.
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Results
Sst-RBS Is Capable of Transducing 293/SSTR-5 Cells at Levels Comparable to
Wild-type Transduction of NIH 3T3 Cells
To begin investigating Sst-RBS transduction capacity, I compared its transduction
with WT and VSV G pseudotyped MLV particles by end-point dilution titration (Figure
3-1A). In four independent titrations, the mean LacZ transducing units per ml of Sst-RBS
reached 5.6 x 105 (range of 2.5 x 105-1.0 x 106) in SSTR-5 expressing cells, WT reached
5.8 x 105 (range of 2.5 x 105-1.0 x 106) in NIH 3T3 cells expressing the natural receptor
and VSV G reached 1.1 x 106 (range of 1.0 x 105-2.5 x 106) in 293 cells (Figure 3-1B).
Pseudovirion Binding to SSTR-5 Is Comparable to mCAT-1
When comparing the level of infection of the Sst-RBS glycoprotein to that of WT, it is
important to maintain comparable numbers of available binding sites on each of the cell
lines. To do this, a binding assay was performed with both pseudovirions. This assay is
described in detail in the virus binding assay section of Chapter 2. Briefly, 293/SSTR-5
cells and NIH 3T3 cells were incubated with the appropriate virus and levels of
attachment were quantified by flow cytometry using antiserum to the MLV SU Env
(Figure 3-2A). The mean fluorescent intensity (MFI) of the bound virus can be used as a
measure of the relative number of pseudovirion binding sites since the anti-SU
antiserum appeared to recognize the Sst-RBS and WT Env similarly in immunoblots
[25]. In three independent assays, Sst-RBS MLV showed a mean increase of 2.9 ± 0.7fold in binding to SSTR-5 expressing cells over cells incubated with antibody alone and
WT MLV showed a mean increase of 4.3 ± 0.2-fold. Histograms from a representative
assay are shown in Figure 3-2B. Because these receptors are multi-membrane
spanning proteins virus binding kinetics cannot be accurately determined; however, the
difference in the level of virus binding to these cells indicates that the binding of WT to
the murine cell line NIH 3T3 is only slightly greater than the capacity for Sst-RBS binding
to SSTR-5 expressing cell. Thus, the effective number of receptor binding sites can also
be considered comparable assuming that the receptors display similar off-rates.
A Non-flexible Turn Flanking the SST-14 Ligand Insertion Is Required for Sst-RBS
Infectivity
A primary reason for the failure of many Env retargeting designs can be attributed to
improper structural relationships and protein folding. Incorrectly folded glycoproteins
might not be incorporated into the viral membrane or fail to complete membrane fusion
because critical conformational changes are impeded [11, 46]. Replacing the natural
RBS minimizes this concern by leaving critical residues in the amino-terminus free [8],
however steric hindrances may still exist that prevent efficient transduction. As such, it
has been shown that the addition of flexible peptides might alleviate these constraints
[14, 47].
To determine if structural requirements of the Sst-RBS glycoprotein have an effect
on transduction capacity, mutagenic PCR techniques were used to alter the Sst-RBS
insertion sequence by replacing the amino- or carboxy-flanking sides of the SST-14
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Figure 3-1. Sst-RBS glycoprotein targets entry at levels comparable to those of
entry mediated by wild-type Moloney murine leukemia virus glycoprotein and
approaching those of VSV G pseudovirions
A. Experimental time line for transduction assays.
B. NIH 3T3, 293, or 293/SSTR-5 cells were exposed to 10-fold serial dilutions of
independently produced MLV vectors pseudotyped with the Sst-RBS (left) WT (middle)
or VSV G (right) envelope glycoprotein and the titers were calculated from the endpoint
dilutions. Data represent the mean ± SD of 3-4 independent titrations (n=4).

16

Figure 3-2. Generation of a host cell line stably expressing levels of target
receptor SSTR comparable to the levels of ecotropic receptor on NIH 3T3 cells
A. Experimental time line for virus binding assay.
B. 293 cells were transfected with a cDNA-encoding human SSTR-5 with an aminoterminal HA epitope tag, selected for G418 resistance and further selected for surface
expression of the target receptor by three rounds of FACS using anti-HA antibody,
yielding a population of cells designated 293/SSTR-5 .The 293/SSTR-5 (left) or NIH 3T3
(right) cells were incubated with Sst-RBS or WT pseudovirions or mock incubated (No
virus), and then both samples were incubated with goat anti-SU antiserum followed by a
mouse anti-goat Alexa488-conjugated secondary antibody plus propidium iodide at the
temperatures indicated in the experimental time and analyzed by flow cytometry. The
histograms shown are representative of the results of three independent binding
experiments. Values shown represent the mean fold increase in Alexa488 intensities
determined with live (propidium iodide-negative) cells.

17

ligand with the flexible residues SGG or SGGGG, respectively (Figure 3-3). End-point
dilutions were performed using pseudovirions coated with these glycoproteins. The
mean titers of three independent titrations of the flexible linker-modified viruses obtained
from 293/SSTR-5 cells are presented in Figure 3-4A. Modifying the flanking sequences
of Sst-RBS did not improve infection and, in fact, placing a flexible sequence before the
SST-14 ligand had a deleterious effect. Only the level of infection of Sst-RBS-3 was
comparable to the original Sst-RBS construct and levels of WT infection on NIH 3T3
cells. Infection of Sst-RBS-2 and Sst-RBS-4 were both decreased.
SDS-PAGE western blot analysis was performed on concentrated pellets obtained
from supernatants of WT, Sst-RBS and Sst-RBS-2 through 4 and probed with anti-SU
antiserum. The MLV capsid (CA) protein served as a loading control since each virus
particle contains approximately the same amount of this protein. The SU and CA band
intensities were quantitated and the intensity of each SU band was normalized to the
amount of respective CA (Figure 3-4B). Sst-RBS displayed a band intensity that was
only slightly lower than the intensity of the WT band. In contrast, Sst-RBS-2, -3 and -4
had reduced band intensities indicating that the modifications to these glycoproteins
caused decreases in their incorporation into the viral membrane possibly because the
glycoproteins were unable to fold into the correct conformation.
Sst-RBS Pseudotyped Lentiviral Vectors
To further characterize the usefulness of Sst-RBS, HIV-based SIN lentiviral vectors
transducing the far-red fluorescent protein mKate2 and firefly luciferase were
pseudotyped with Sst-RBS (Sst-RBS LV) or VSV G (VSV G LV), concentrated and
certified replication incompetent by the UTHSC Viral Vector Core. Transducing units
(TU/ml) of these vectors were quantified by end-point dilution titration on 293/SSTR-5
and 293 cells using a standard luciferase assay by the vector core. The VSV G LV stock

Figure 3-3. Modified Sst-RBS glycoproteins containing the SST-14 ligand
BOLD text indicates linker sequences, italic text indicates disulfide bonded cysteine
residues, underlined text indicates SST-14 replacement sequence, and
highlighted text indicates residues required for receptor binding.
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Figure 3-4. Glycoproteins with a non-flexible peptide linker sequence upstream
of the SST-14 ligand retain infectivity
A. Ten-fold dilutions of MLV virions coated with Sst-RBS, the flexible-linker modified SstRBS-2, -3, and -4 (purple) or WT (black) glycoproteins were exposed to 293/SSTR-5 or
NIH 3T3 cells and infection scored by LacZ transduction (unpublished data). The
presence or absence of amino- and carboxy-flanking flexible residues is indicated under
the bars corresponding to each pseudovirus. Data represent the mean ± SD of 3
independent titrations (n=4).
B. SDS PAGE Western Blot was performed on concentrated virus pellets from a
representative production of the pseudovirions in (A) (unpublished data). The membrane
was probed with goat-anti p70/SU recognizing the MLV glycoprotein, stripped and reprobed with goat-anti p30/CA recognizing the MLV capsid protein as an indication of the
overall virus particles present in each sample.
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contained 2.3 x 109 luciferase TU/ml and the Sst-RBS LV stock contained 9.2 x 106
luciferase TU/ml. This represents an approximate 200-fold difference in titer between
VSV G and Sst-RBS LV. This is similar to titers of other retroviral glycoprotein
pseudotypes of lentiviral vectors and is thought to result from lower assembly of other
glycoproteins compared to VSV G due to their cytoplasmic tail sequences [23, 48, 49].
Sst-RBS and VSV G LV particles transducing GFP under the control of the hUbC
promoter (Figure 3-5A) were produced in an effort to detect transduction by flow
cytometry analysis. In accordance with the difference in luciferase TU/ml, the MFI of
VSV G LV transduced 293/SSTR-5 cells was detected well above the background MFI
of mock exposed cells while Sst-RBS LV transduction could not be detected. When the
promoter element of this HIV-based genomic construct was replaced with the hEF1α
promoter, the MFI of both constructs increased so that Sst-RBS transduction of SSTR-5
expressing cells was detectable; however, VSV G transduction was 20.2-fold higher
(Figure 3-5B).
Discussion
Many RV and LV receptors are multiple membrane spanning proteins such as the
chemokine co-receptors used by HIV [50], Xpr1 used by xenotropic MLV [51] and
mCAT-1, the natural Moloney MLV receptor [52]. Although SSTR are not entry receptors
for any known virus they also have multiple membrane spanning domains. Conversely,
the epidermal growth factor (EGF) receptor (ErbB) has a single transmembrane domain.
Chimeric virions containing an insertion of EGF in amphotropic [53] or Moloney [54] MLV
Envs were capable of binding ErbB but no transduction was seen. These observations
lead both Cosset and Katane’s groups to propose that receptor characteristics are the
main consideration for developing an entry targeted viral vector, possibly because
receptors that span the cellular membrane multiple times would bring bound virus into
close contact with the cell [54]. Additionally, polytopic receptors such as these are often
localized in cholesterol-rich lipid rafts which are crucial for the endocytosis and entry of
many of enveloped viruses [55].
Research conducted while characterizing the Sst-RBS glycoprotein demonstrates
that properties of the targeting glycoprotein are also an important parameter. Viral
glycoproteins naturally assemble onto virions in a metastable conformation that is not
competent for membrane fusion. In the case of gammaretroviral Env, the transition from
a metastable to a fusion competent conformation is induced after receptor binding and
begins with cleavage by host cell cathepsin proteases in the late endosomal
compartment which subsequently triggers isomerization of the disulfide bond between
SU and TM domains of Env [56]. These conformational changes expose the TM fusion
peptide that is responsible for completing the membrane fusion process [57]. It follows
that the Env sequences that bind natural retrovirus receptors possess the ability to
initiate and sustain these critical conformation changes. This capacity most likely derives
from the position of the RBS at the top of the receptor binding domain, and while this
location may not be the only one with the capacity to initiate and sustain membrane
fusion, it is the most effective one discovered to date [25]. Furthermore, the low level of
LacZ transduction observed with Sst-RBS-2 and -4 coated viruses correlated with low
levels of anti-SU probe signal in a western blot analysis (Figure 3-4), indicating that
placing flexible sequences in this important region affected glycoprotein incorporation
into the virion envelope. It is interesting that Sst-RBS-3 displayed a similar SU band
intensity as Sst-RBS-2 and -4 but retained the same level of transduction as the original
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Figure 3-5. Lentivirus transducing an EF1α-GFP transgene exhibits higher
expression
A. Schematic representation of the HIV-1 based SIN-lentiviral expression genomes. Both
plasmids contain a CMV enhancer element substituted for the U3 region of the 5’ LTR
and a deleted 3’ U3 region rendering the 5’ LTR of the integrated provirus inactive.
FUGW (top) transduces a GFP reporter sequence under the human Ubiquitin C
promoter (hUbC) and FEGW (bottom) transduces GFP under the human Elongation
Factor 1-alpha promoter (hEF1α). R, repeat region; U5, unique 5’ untranslated region;
HIV-1 FLAP, enhances titer by increasing cDNA nuclear import; EGFP, enhanced green
fluorescent protein; WRE, woodchuck hepatitis posttranscriptional regulatory element;
∆U3, unique 3’ untranslated region deletion.
B. 293/SSTR-5 cells were exposed to mock (white bars) or unconcentrated VSV G (left
panel) or Sst-RBS (right panel) coated lentiviral vectors transducing either FUGW (light
bars) or FEGW (dark bars) and assayed by flow cytometry analysis 72 hours post
infection for GFP fluorescence at the times indicated in the experimental timeline.
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Sst-RBS glycoprotein. Sst-RBS also exhibited a decrease in SU band intensity
compared to WT which did not significantly affect its relative level of transduction. This
suggests that the rigid structure provided by the original Sst-RBS insertion sequence
may be a necessary structural element and it is this property, not the overall level of
glycoprotein incorporation, which influenced the levels of transduction.
These data strongly indicate that the chimeric Sst-RBS Env retains the structural
characteristics that are necessary to initiate infection. Despite slightly lower levels of cell
surface binding sites (Figure 3-2) and Sst-RBS Env detection by WB analysis (Figure
3-4) and compared to WT, the Sst-RBS glycoprotein was capable of specifically
delivering genes to cells expressing the SSTR-5 receptor with a transduction efficiency
comparable to WT virus and approaching that of the “gold-standard” VSV G protein
(Figure 3-1) demonstrating that the capacity of Sst-RBS MLV was within the range of a
typical transduction vector. However, the difference in the level of transduction using an
HIV-based LV vector pseudotyped with Sst-RBS or VSV G was larger than the
difference seen from MLV particles pseudotyped with these Envs (Figure 3-5). The
ability to transduce non-dividing cells is a distinct advantage of using LV vectors in in
vivo systems. The influence of the 100-fold lower relative transduction capacity of SstRBS LV compared to Sst-RBS coated MLV-based vectors as measured in cultured host
cells would likely be outweighed by the mitotic requirement for MLV integration. There is
a need for an in vivo targeting vector that is capable of directing high capacity
transduction to particular cell or tissue types of interest. This chapter demonstrated that,
in addition to the position of the targeting ligand, the structure of Sst-RBS glycoprotein
allowed a high level of transduction. Hence, the Sst-RBS glycoprotein is a suitable
candidate for mediating in vivo targeted transduction.
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Chapter 4. Characteristics of the Cellular Receptor Influence the Intracellular Fate
and Efficiency of Retrovirus Infection ‡
Introduction
Viral glycoproteins and their host cell entry receptors are thought to have co-evolved
[58]. Data presented in Chapter 3 and published previously [25] highlighted the
importance of glycoprotein characteristics on the efficiency of Sst-RBS-mediated
transduction. While specific traits of the viral glycoproteins likely represented a major
selective pressure driving the choice of receptor during that co-evolution [59],
characteristics of candidate host cell receptors are also suspected of being involved but
their possible influence has been difficult to assess [16, 60]. Virus-receptor complexes
are internalized by existing endocytic mechanisms such as classical clathrin-mediated,
caveolar/lipid raft associated, macropinocytosis, and phagocytosis [55, 61]. After
budding from the plasma membrane, vesicles formed by these endocytic mechanisms
become early endosomes (EE). As EEs mature into late endosomes (LE), the pH of their
intralumenal environment decreases from physiological pH to as low as 5.0. Maturation
is a dynamic process in which endocytosed cargo is sorted, numerous intralumenal
vesicles are formed and various types of recycling vesicles bud off under the direction of
numerous Rab GTPases and their associated effector molecules. During this process,
the contents of endosomes are acted on by multiple cellular proteases that become
activated as the pH decreases. LEs eventually fuse with lysosomes where the pH drops
even further sustaining a highly acidic and proteolytically degradative environment [62].
Several pieces of circumstantial evidence suggest that the fate of internalized virusreceptor complexes can strongly influence infection outcomes and thereby could have
exerted selective pressure on the choice of a cellular receptor during evolution of viral
glycoproteins. First, the Ebola virus fusion receptor (Neimann-Pick C1, NPC1) and
activating host cell protease (cathepsin B) reside in a specific intracellular compartment
[63, 64], suggesting that only filoviruses internalized into that compartment undergo
efficient, productive entry. Second, inhibiting lysosomal degradation using
pharmacologic agents increased infection by HIV-1 and the betaretrovirus enzootic nasal
tumor virus (ENTV) [65-67], suggesting that internalization into degradative
compartments can negatively impact the efficiency of entry. Third, specific inhibition of
host cell cathepsin B increased infection of VSV G pseudotyped MLV [7] further
suggesting that certain degradative compartments can be less productive destinations
for entry. Lastly, prolonged neutralization of intracellular compartments decreased
infection of the alpharetrovirus avian sarcoma and leukosis virus subgroup A (ASLV-A)
[68] and re-routed virus-receptor complexes to different compartments [69], suggesting
that the alternative compartments were less permissive than the compartment to which
the virus normally traffics.
The studies reported in this chapter took advantage of the unique opportunity
provided by the Sst-RBS modified Env and its capacity to transduce cells by multiple
cellular receptors to directly interrogate the influence of intracellular trafficking of
internalized virus-receptor complexes on infection; asking if this characteristic of an entry
‡

Adapted with permission. Krueger, R.L. and L. M. Albritton. Characteristics of the
cellular receptor influence the intracellular fate and efficiency of retrovirus infection. J
Virol, 2013. 87(10): p5916-5925.
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receptor influences infection. Subtypes SSTR-2, -3 and -5 were selected for this study
because they are similar structurally and pharmacologically (e.g., kinetics of agonist
binding and internalization) but have documented differences in intracellular trafficking
that result in distinct intracellular fates after internalization (reviewed in [34]). SSTR-1
and -4 were not included because they are not as efficiently internalized as the other
subtypes after agonist exposure [30]. I quantified Sst-RBS pseudovirion infection on host
293 cell lines stably expressing cell surface SSTR-2, -3 and -5 at levels comparable to
each other, and to endogenous mCAT-1 expression on murine NIH 3T3 cells. This new
model system circumvents the major technical constraints that have limited previous
studies because the types of endocytic pathways and vesicular trafficking proteins
available during infection are equivalent due to their 293 background. Additionally, the
density of receptors and capacity for virus internalization are also comparable amongst
the cell lines which were exposed to the same pseudovirus. Thus, differences in
intracellular trafficking of internalized virus-receptor complexes should constitute the
predominant influence on infection. Transduction assays revealed that Sst-RBS MLV
and LV pseudotype transduction of the SSTR-2 and -3 cell lines was substantially lower
than in the SSTR-5 expressing cells. Taken together the results of virus binding,
internalization rate, lysosomatropic agent, protease inhibitor and penetration assays
using quantitative real-time PCR support that infection via SSTR-5 is greater because
viruses internalized by this subtype are directed to more permissive intracellular
compartments, specifically to ones that are more favorable to penetration of the viral
nucleocapsid than those compartments to which viruses bound to subtypes 2 and 3 are
directed. These studies suggest that receptor characteristics such as intracellular
trafficking exert a strong influence on the efficiency of infection and may have provided a
selective pressure during retrovirus evolution guiding the choice of a host cell receptor.
Results
Infection of Sst-RBS Pseudotyped Viruses Is Greatest via SSTR-5
Chapter 3 described the generation and characterization of a population of 293 cells
stably expressing cell surface SSTR-5 at levels comparable to the relative number of
endogenous ecotropic receptors (mCAT-1) on murine NIH 3T3 cells (Figure 3-2). For
these studies, two additional stable cell lines were sorted for levels of SSTR-2 and -3
comparable to that of the previously established 293/SSTR-5 cells (Figure 4-1) using an
HA epitope tag present on each receptor subtype’s extracellular amino-terminus. Fusion
of the HA tag sequence in this position does not alter agonist binding or internalization
[35]. These matched cell populations were exposed to equal volumes of serially diluted
Sst-RBS, WT MLV or VSV G MLV and the level of LacZ transduction assessed by end
point dilution titration. Surprisingly, transduction was 222-fold and 23-fold lower in
293/SSTR-2 and -3 cells, respectively, compared to the 293/SSTR-5 cells (Figure
4-2A). Infection of control VSV G MLV and LV pseudovirions was comparable in each of
the cell types indicating that the observed infectivity differences were Sst-RBS- and
receptor subtype-dependent and thus not due to unspecific differences between the cell
lines. There was no observable infection of the parent 293 cells. The SST-14 ligand is
capable of binding endogenous murine somatostatin receptors [27] and a low level of
infection (7.5 ± 1.4 TU/ml) was observed in NIH 3T3 cells exposed to Sst-RBS MLV.
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Figure 4-1. SSTR-expressing cell populations display comparable levels of target
receptors on their cell surface
The steady state level of each SSTR subtype was quantified by flow cytometry using
monoclonal antibody to the HA epitope tag located on the extracellular, amino-terminus
of each receptor subtype. Representative histograms (purple, 293 cells expressing
SSTR subtypes; black, background binding of the antibody to control 293 cells) are
shown with values indicating the fold increase in mean fluorescent intensity over control
293 cells.
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Figure 4-2. Infection of pseudotyped viruses is greatest via SSTR-5
A. 293 cells or the receptor matched 293/SSTR-2, -3, or -5 populations were exposed to
ten-fold serial dilutions of Sst-RBS (purple bars), VSV G (white bars) or WT (black bars)
pseudotyped MLV, spinoculated and incubated at 37 °C overnight. The level of infection
was determined after 48 hours by scoring LacZ positive cells under a light microscope.
B. Sst-RBS [5X] or VSV G (10-2) pseudotyped LV was exposed to each of the indicated
cell types, spinoculated and incubated at 37 °C overnight. The level of infection was
determined after 72 hours by flow cytometry analysis of GFP positive cells.
Values represent the mean ± SD of 3 independent titrations (n=4). P-values were
calculated by one way ANOVA and Bonferroni posttest. *, p ≤ 0.05; **, p ≤ 0.01.
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The trend observed with the MLV pseudovirions was also observed in five
independent lentivirus infection assays using two pseudovirion stocks. Sst-RBS and
VSV G LV particles transducing GFP were produced and the infectivity in 293,
293/SSTR-2, -3, and -5 cells was analyzed by flow cytometry at 72 hpi. Sst-RBS
mediated transduction was greater in SSTR-5 expressing cells with a mean of 0.9 ± 0.5
percent of cells expressing green fluorescence above the background levels in 293 cells
(Figure 4-2B). In each of the three experiments a few GFP positive foci were observed
in the 293/SSTR-2 and -3 populations and no GFP expression was observed in 293 cells
by visual inspection using fluorescent microscopy prior to detachment for flow cytometry.
However, the difference between the actual MFI of the SSTR-2 and -3 cells (8.4 x 102
and 7.4 x 102, respectively) and the background MFI of the 293 cells (6.2 x 102) was not
statistically significant indicating that the low level of infection seen by visual inspection
was below the level of detection by flow cytometry, evidently because the transduced
cells represented an extremely low percentage of total cells. In two additional
experiments, end-point dilution titration of LV transducing a puromycin resistance gene
supported the flow cytometry results. Sst-RBS LV titers averaged 1 x 104 TU/ml in
293/SSTR-5 cells and zero in 293/SSTR-2 and -3 cells (no puromycin resistant colonies
observed). VSV G LV displayed titers of greater than 1 x 105 TU/ml in all cell lines. The
lower infection of Sst-RBS LV compared to VSV G pseudotypes was consistent with
previous results; when pseudotyped on MLV, the entry capacity of Sst-RBS showed a
mean of 2.7 which ranged up to 5-fold of VSV G (Figure 3-1) but was 200-fold less
effective on LV pseudovirions as measured by luciferase transduction. In accordance
with the GFP transduction results, a p24 ELISA of a parallel production of Sst-RBS and
VSV G LV pseudovirions used in the flow cytometry analysis revealed a 2.3 fold
difference in the number of physical particles (data not shown).
Receptor Specific Interactions Mediate Sst-RBS MLV Infection
Sst-RBS MLV infection of SSTR-2 expressing cells was previously shown to be
specific to this subtype as judged by dose-dependent inhibition by exogenous SST-14
peptide [25]. To confirm that receptor specificity is retained by SSTR-3 and -5, end-point
dilution titration was performed in the presence and absence of 1 µM of the SST-14
peptide (Figure 4-3A). Sst-RBS MLV was competitively inhibited in each of the SSTRexpressing cells by more than 80% (Figure 4-3B). Infection of NIH 3T3 cells by WT MLV
or the SSTR expressing cells by VSV G MLV was unaffected by the presence of SST-14
(Figure 4-3C).The downstream effects of ligand-somatostatin receptor binding, signal
transduction events and receptor desensitization are complex and can vary depending
on the ligand and cell type [29, 30, 34, 36]. One important potential outcome involves the
initiation of anti-proliferative signals within the cell [29] which is especially relevant to the
life cycle of MLV because proviral integration into the host chromosome is highly
dependent on the mitotic stage of cell division [9]. To determine if SSTR engagement
affects the cell’s ability to divide, the number of cells in each VSV G MLV positive foci (a
cluster of β-galactosidase positive cells resulting from the division of one infected cell)
was enumerated in the SST-14 treated and untreated populations from Figure 4-3C. If
anti-proliferative signals are initiated through the SSTRs then the number of cells in each
positive foci will be less in the SST-14 treated population than in the untreated cells.
However, the mean number of cell divisions did not vary significantly among any of the
SSTR cell types (Figure 4-4) indicating that the observed inhibition of infection via
SSTR-2 and-3 was not due to a reduction in host cell division.

27

Figure 4-3. Receptor-specific interactions mediate Sst-RBS MLV infection
A. Experimental time line for transduction in the presence of SST-14 inhibitor.
B. Sst-RBS MLV infection was inhibited by preabsorption of cells with the SSTR agonist,
SST-14. 293, 293/SSTR-2, -3, and -5 cells were incubated with 1 µM SST-14 peptide or
mock-treated for 30 minutes prior to spinoculation of Sst-RBS MLV (purple bars) in the
presence of 1 µM SST-14 or mock treated. Values show the mean relative infection ±
SD in the presence of the peptide, calculated as (infection in the presence of SST-14 /
infection in its absence) x 100.
C. The peptide agonist did not affect infection of control pseudovirions. Cells were
treated as in (A) except that infection was performed with VSV G (white bars) or WT
(black bars) MLV pseudovirion stocks.
All values represent the mean ± SD of three independent experiments (n=4). P values
were calculated using two way ANOVA and Bonferroni post test. *, p ≤ 0.05; **, p ≤ 0.01.
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Figure 4-4. The SST-14 ligand does not act by inhibiting cell division
The mean number of cell divisions was determined by counting the number of cells in
each β-galactosidase-positive foci from the VSV G MLV data in Figure 4-3B.
All values represent the mean ± SD of three independent experiments (n=4). P values
were calculated using two way ANOVA and Bonferroni posttest. *, p ≤ 0.05; **, p ≤ 0.01.
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The Relative Level of Cell-associated Virus Can Not Account for Differences in
Transduction
Although SSTR-2, -3 and -5 reportedly bind SST-14 with similar affinity [29], binding
affinities between these somatostatin receptors and other ligands vary. For instance,
while SSTR-2 and SSTR-3 bind the SST-28 precursor with comparable affinity to
SST-14, SSTR-5 has a higher affinity for SST-28 [27, 30]. Furthermore, Octreotide, a
synthetic peptide that mimics the agonist effects of the natural SST ligand, binds
SSTR-2 with a higher affinity than both SSTR-3 and SSTR-5 [27, 34]. If binding to
SSTR-2 and -3 is compromised by placing SST-14 in the larger context of the MLV Env,
then increased infection of 293/SSTR-5 cells would be expected as the result of greater
pseudovirion attachment. To investigate this possibility, equilibrium virus binding assays
were performed as previously described [42, 70]. Briefly, each of the SSTR-expressing
cell lines were incubated with Sst-RBS MLV pseudovirions and the relative levels of
attachment were quantified by flow cytometry using anti-SU antiserum. In three
independent assays, Sst-RBS MLV showed a mean increase of 2.89 ± 0.7-fold in
binding to 293/SSTR-5 over cells incubated with antibodies alone; an increase that was
not significantly different from the mean for SSTR-2 and -3 cells (2.27 ± 0.6 and
2.54 ± 0.3-fold, respectively). The histograms from a representative assay are shown in
Figure 4-5A. However, Sst-RBS binding to 293 cells was also similar indicating that a
majority of detectable virus binding can be attributed to a cellular factor common to 293
cells. An additional limitation of these results is that virus-receptor complexes
internalized during the 37 °C binding step would not be accounted for in this
quantification of surface pseudovirions. Additional experiments in which the binding step
was carried out at 4 °C to inhibit virus-receptor complex internalization yielded only
background levels of Sst-RBS and WT MLV binding (data not shown), findings
consistent with previous reports that MLV binding at lower temperatures is limited [70,
71].
To address the extent of virus-receptor complex internalization and control for virus
associated with the SSTR-expressing cell lines due to their 293 cell parentage, a
quantitative real-time PCR assay was designed to take advantage of the unique
characteristic of many retroviruses, including MLV, wherein reverse transcription of
genomic RNA (gRNA) has been primed and the Minus Strand Strong Stop (MSS) cDNA
generated and packaged into mature virions along with the gRNA [72]. Using a primer
set designed to specifically amplify the MSS species (Figure 4-5B); the relative level of
receptor-associated virus particles (i.e. the amount of virus both internalized and bound
at the cell surface) was measured as a more precise quantification of total virus.
Internalization of virus was synchronized in each of the SSTR-expressing cell lines by
spinoculation at 4 °C prior to shifting cells to 37 °C. At six hpi the amount of MSS cDNA
was quantified by quantitative real-time PCR. There were no statistically significant
differences in the fold increase of virus associated with each of the SSTR subtypes
(Figure 4-5C). The amount of virus associated with each of the SSTR-expressing cell
lines was also comparable at zero hpi (no 37 °C shift) with mean relative fold increases
of 1.1, 1.1 and 0.86 while the mean increases after 6 hours were 0.93, 1.3, and 0.99 for
SSTR-2, SSTR-3 and SSTR-5; respectively. The difference between the amounts of cell
associated virus at zero and 6 hpi in each cell line was not significantly different
indicating that the MSS signal was not amplified during the 6 hour incubation and that
the MSS cDNA was synthesized in the mature virion prior to the start of the experiment.
Together these experiments indicated that there are no differences in virus binding or,

30

Figure 4-5. The relative level of cell-associated virus is comparable for each
SSTR-expressing cell line
A. Equilibrium virus binding assay was performed using Sst-RBS MLV incubated with
293 or SSTR-expressing cells (binding to 293 cells is unpublished data). Antiserum to
the MLV glycoprotein was used to detect surface-bound virus by flow cytometry analysis.
Representative histograms and values indicating the fold increase in MFI ± SD from
three independent experiments are shown with surface-bound virus (purple) next to their
mock-exposed counterparts (gray).
B. Schematic showing the location of quantitative real-time PCR amplicons within the
recombinant MLV genome used in infection experiments. U3, unique 3’ untranslated
region, R, repeat sequence. U5, unique 5’ untranslated region. LacZ, β-galactosidase
gene. SV40, simian virus 40 promoter. Neo r, neomycin resistance gene.
C. Cells were exposed to Sst-RBS MLV or mock medium and spinoculated at 4 °C then
shifted to 37 °C to allow internalization. After six hours unbound virus was removed and
cells were lysed and isolated DNA was used directly as the template for quantitative
real-time PCR. The level of cell-associated virus in the SSTR-expressing cells was
determined as the relative fold increase of the MSS amplicon for each SSTR expressing
cell line over the 293 signal (representing background binding) normalized to
endogenous β-actin. No amplification was detected in mock-exposed cells. Data
represent three independent experiments (n=3). Significance was calculated using one
way ANOVA and Bonferroni posttest P value >0.5.
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importantly, in the amount of cell-associated virus that can account for the higher level of
infection via SSTR-5.
Infection of Sst-RBS Pseudovirions Requires Internalization
Additional experiments were performed to investigate the nature of the differences
in infection of the three receptor subtypes. WT MLV is internalized by caveolinassociated endocytosis when bound to its natural receptor on NIH 3T3 cells [5], while
the SSTR utilize clathrin-mediated endocytosis following SST-14 binding [30, 34]. To
begin examining the possibility that internalization of Sst-RBS MLV bound to the three
somatostatin receptor subtypes differs, infection was quantified in the presence of
inhibitors of endocytosis (Figure 4-6A). Our lab [7, 43] and others [67, 73-75] have
published the use of these inhibitors within the ranges indicated in this study with no
detectable toxicity. To facilitate comparison to these previous publications, experiments
were designed to use at least one “low” and “high” concentration within this range.
Nocodazole, an inhibitor of microtubule polymerization that interferes with endocytic
pathways used during virus entry. Nocodazole induced similar decreases in infection in
all cell lines (Figure 4-6B), indicating that both WT and Sst-RBS MLV require
endocytosis and, consequently, that the pseudovirions are not fusing at the cell surface.
Infection was also carried out in host cells pre-incubated with methyl-β-cyclodextrin
(MβCD) which sequesters cholesterol and disrupts lipid rafts. Cholesterol-dependent
endocytic pathways are strongly inhibited by this drug. Interestingly, infection via
SSTR-5 exhibited a mean inhibition of 43.0% to the lowest concentration of the drug that
was similar to the level of sensitivity of control WT MLV on mCAT-1 in NIH 3T3 cells
(mean of 37.9% inhibition). Infection of 293/SSTR-2 and -3 cells was also sensitive to
MβCD (means of 18.3 and 24.4% inhibition, respectively) although the lower mean
inhibitions were not statistically different from the means for SSTR-5 or NIH 3T3 (Figure
4-6C). While these results confirm that internalization is required for entry via all three
SSTR subtypes, it is also noteworthy that entry of Sst-RBS MLV through SSTR-5
showed a cholesterol-dependence that was more similar to WT MLV on NIH 3T3 cells
than to entry via the other two SSTR subtypes.
A Slower Rate of Internalization Correlates with Enhanced Infection
The efficiency of receptor internalization was evaluated by incubating the SSTR
subtype expressing cell lines with 1 µM SST-14 or mock treatment for 30 minutes at 4 °C
or 37 °C to stimulate receptor internalization. Cells were then incubated for 1 hour at
4 °C with mouse anti-HA.11 monoclonal antibody (Figure 4-7A). A decreased MFI after
treatment with 1 µM SST-14 was viewed as evidence that SSTR internalization
occurred. The amount of internalization of each of the receptor subtypes at 4 °C (at
which temperature receptor internalization should be inhibited) was then compared to
the amount of internalization at 37 °C. The profile of 293 cells (which do not express any
HA-tagged SSTR) does not change while the peaks for SSTR-2 and -3 reveal receptor
internalization at 37 °C, each representing a mean fold increase in internalization of 27
over that of control 293 cells. However, the peaks for SSTR-5 remain static, representing
a mean fold increase in internalization of 8.8 (Figure 4-7B). This incongruence with
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Figure 4-6. Infection of Sst-RBS pseudovirions requires internalization
A. Experimental time line for drug inhibitor studies.
B and C. 293, 293/SSTR-2,-3 and -5 or NIH 3T3 cells were pretreated with (B) DMSO,
33 µM or 66 µM nocodazole for 1 hour or (C) H2O, 1 mM or 0.5 mM MβCD for 30
minutes then exposed to Sst-RBS or WT MLV maintaining drug or vehicle. Infection was
scored with Romanizer software for the presence of β-galactosidase positive cells at 48
hpi. Relative infection was calculated as the percentage of infection compared to the
vehicle only treated cells. No transduction was observed in 293 cells (data not shown).
Data represent the mean ± SD of three independent experiments (n=4). P values were
calculated by using two way ANOVA and Bonferroni posttest. NS, Not Significant;
*, p ≤ 0.05; **, p ≤ 0.01.
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Figure 4-7. Patterns of receptor internalization among SSTR subtypes
A. Experimental time line for receptor internalization study.
B. Representative histograms indicating the level of cell surface receptor after 30
minutes in the absence or presence of 1 µM SST-14 ligand at 4 °C or 37 °C as
determined by flow cytometry using the HA epitope tag located on the amino-terminus of
each SSTR subtype (unpublished data). 293 cells do not express HA tagged SSTR.
Decreased MFI of peaks at 37 °C with 1 µM SST-14 indicate internalization of surface
receptors.
C. Relative internalization of HA-tagged SSTR in each cell line (unpublished data). The
relative internalization was calculated by comparing the MFI of SST-14 treated cells at
4 °C to the MFI of SST-14 treated cells at 37 °C and expressed as the mean fold
increase in internalization, as indicated below the respective bar.
Data represent the mean ± SD of three independent experiments. Significance was
calculated by using two way ANOVA and Bonferroni posttest P value >0.5.
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infection results lead to the hypothesis that SSTR-5 was internalized more slowly than
SSTR-2 and -3.
Thus, the kinetics of virus-receptor complex internalization were directly investigated
by examining the level of infection over time and under conditions in which virus
attachment was synchronized and non-internalized virus was inactivated at early time
points. Attachment was synchronized by spinoculation at 4 °C and internalization of
bound virus was initiated by shifting the cultures to 37 °C. At various times after the
temperature shift, non-internalized virus was inactivated by a low-pH citrate wash and
infection was allowed to continue (Figure 4-8A). The level of transduction at each time
point was normalized to the values obtained at one hour; at which time infection had
reached an average of 92.1% of the levels obtained from overnight exposure of the
same virus stocks on 293/SSTR-5 (data not shown). The normalized levels of
transduction were graphed and the slope of each curve calculated by non-linear
regression analysis to determine the relative rates of internalization (percentage per
minute) for each virus-receptor combination. Surprisingly, Sst-RBS MLV was internalized
faster in 293/SSTR-2 and -3 cells (Figure 4-8B) as indicated by 50% of infectious virus
(T50) having been internalized at 12.4 and 13.3 minutes, respectively, compared to 19.7
minutes in SSTR-5 expressing cells. Like the outcome of MβCD treatment, the T50 in
SSTR-5 cells was similar to that of WT MLV in NIH 3T3 cells (17.7 minutes). No infection
of either virus was seen in the parent 293 cells.
SSTR-5 Directs Virus to a More Permissive Environment
The differences in internalization presented in Figure 4-8 strongly suggest that entry
through SSTR-5 may be directing Sst-RBS MLV to an intracellular environment that is
more permissive for infection. To investigate this possibility, infection was examined in
the presence of bafilomycin A1 (BafA) (a vacuolar ATPase inhibitor). This drug interferes
with the acidification of endosomes and is commonly used to determine the pH
requirements of the membrane fusion step during entry [55]. For example, WT MLV is
not inhibited by BafA while VSV G mediated infection is profoundly decreased [73].
Unexpectedly, BafA enhanced, rather than reduced, infection through SSTR-2 (mean
transduction increased from 2.9 ±1.6 TU/ml in DMSO treated cells to 7.5 ± 4.1 x 101
TU/ml in cells treated with 10 nM BafA) and SSTR-3 (from 8.6 ± 3.1 to 22 ± 6.4 x 101
TU/ml); whereas Sst-RBS MLV infection via SSTR-5 (from 2.6 ± 0.6 to 2.0 ± 0.9 x 103
TU/ml) was not significantly affected by the drug (Figure 4-9A). While BafA enhanced
infection via SSTR-2 and -3, the total amount of transduction remained logs below that
seen in 293/SSTR-5 cells or in WT-MLV infection of NIH 3T3 cells. These results are
consistent with exposure to an acidic environment, such as that found in late
endosomes, inhibiting Sst-RBS MLV infection through SSTR-2 and -3 but not through
SSTR-5. Results of infection in the presence of chloroquine (Chlor) (a weak base that
accumulates in lysosomal compartments) were uninformative in that similar inhibition
was observed in all cell types (Figure 4-9B). However, monensin had a more marked
effect on infection in 293/SSTR-2 than BafA. A member of the carboxylic ionophore
class of drugs monensin functions as a sodium ion exchanger also raising the pH of
lysosomal compartments [6, 55, 76]. Infection through SSTR-2 increased from 13.4 ± 2.6
to 124 ± 59.4 TU/ml in the presence of monensin which represents a 9.9 fold increase
while infection of 293/SSTR-5 was unaffected in its presence (Figure 4-9C).
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Figure 4-8. A slower rate of virion internalization correlates with increased
infection
A. Experimental time line for rate of internalization study.
B. Sst-RBS or WT MLV was spinoculated onto 293, 293/SSTR-2, 3 and 5 or NIH 3T3
cells at 4 °C then shifted to 37 °C for the indicated time to allow internalization. Noninternalized virus was inactivated and infection measured at 48 hpi by counting LacZ
positive cells using Romanizer software [44]. Values shown are the relative infection
calculated as (infection at each time point / infection at one hour) x 100. The relative rate
of internalization (% pseudovirions internalized per minute) was calculated as the slope
of each curve using non-linear regression analysis (GraphPad Prism). T50, time required
to obtain 50% infection.
Data represent the mean ± SD of four independent experiments (n=4).
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Figure 4-9. Neutralizing acidic compartments enhances infection via SSTR-2
A, B and C. 293, 293/SSTR-2,-3 and -5 or NIH 3T3 cells were pretreated with (A)
DMSO, 10 nM, 20 nM, or 30 nM BafA (B) H2O, 15 µM or 30 µM Chlor or (C) EtOH, 12.5
µM or 25 µM Monensin prior to Sst-RBS, VSV G or WT MLV exposure, as indicated,
while maintaining the drug or vehicle. Infection was scored with Romanizer software for
the presence of β-galactosidase positive cells at 48 hpi Relative infection was calculated
as the percentage (A, B) or fold increase (C) of infection compared to the vehicle only
treated cells. There was no observable infection of 293 cells in the presence or absence
of chloroquine, but increased to 14 TU/ml at 10 nM BafA, and 14.77 ± 5.3 at 12.5 µM
and 19.07 ± 4.3 TU/ml at 25 µM Monensin.
All data represent the mean ± SD of at least three independent experiments (n=4). P
values were calculated by using two way ANOVA and Bonferroni posttest. *, p ≤ 0.05; **,
p ≤ 0.01.
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Since host cell proteases of the cathepsin family have been shown to be important
in potentiating infection of WT MLV by activating the fusion capacity of the viral
glycoprotein [7, 74], it is possible that SSTR-2 and -3 transport virus to intracellular
compartments containing either an unfavorable type or concentration of protease. To
examine this possibility, infection was performed in the presence of CA074 Me. At low
concentrations, CA074 Me specifically inhibits cathepsin B, while at higher
concentrations it also inhibits other cysteine cathepsins [7]. Infection of Sst-RBS MLV
was reduced at the higher, non-specific concentration but was not changed significantly
at 5 µM for all receptor subtypes, whereas; WT MLV infection of control NIH 3T3 cells
was inhibited significantly at both concentrations (Figure 4-10A). These results suggest
that, in a 293 cell background, cathepsin B is not the predominant protease involved in
entry of Sst-RBS MLV. To further explore the influence of cellular proteases, infection
was quantified in the presence of leupeptin, a lysosomal protease inhibitor. Sst-RBS
MLV infection decreased markedly in 293/SSTR-2 and SSTR-3 while only modest
decreases were seen in 293/SSTR-5 (Figure 4-10B), indicating that the protease
involved in infection through SSTR-5 differs from those encountered by virus internalized
via SSTR-2 and -3. Taken together, I favor the interpretation of these drug studies to
indicate that SSTR-5 directs virus to a distinct intracellular compartment that is highly
favorable for infection, at least in part because it contains a favorable set of cellular
proteases for activation of the Sst-RBS glycoprotein.
Penetration into the Host Cytoplasm Is More Efficient via SSTR-5
If this interpretation is correct, then the greater infection via SSTR-5 could be
explained by more efficient protease activation of virus-cell membrane fusion leading to
greater levels of penetration. To test this hypothesis, the relative amount of virus that
had penetrated the host cell cytoplasm was quantified. In MLV, reverse transcription is
initiated during virion assembly but halts shortly after the MSS cDNA is generated. Then
in a second stage, shown to occur after penetration, the cDNA of internal genes is
synthesized [58, 72]. Based on this attribute, Gao and colleagues developed a
quantitative real-time PCR assay using the amplification signal of an internal gene as a
measure of virus penetration and infection [45]. We adapted this assay to compare
penetration of MLV pseudovirions among the SSTR subtypes by measuring the level of
internal LacZ gene amplification after 6 hours (Figure 4-11A). The schematic in Figure
4-5B shows the location of the amplicon within the internal LacZ gene, as well as the
MSS cDNA amplicon. The LacZ amplification signal for each cell line was normalized to
the MSS signal for the zero and 6 hour incubation times to account for bound but not
internalized virions. Increased LacZ amplification then becomes proportional to the
number of virion cores that penetrate the host cytoplasm. When the normalized LacZ
amplification data were expressed as the relative fold increase from zero to 6 hpi,
293/SSTR-2 and -3 cells showed significantly lower levels of reverse transcription than
293/SSTR-5 cells and NIH 3T3 cells exposed to WT-MLV over the 6 hour time period
(Figure 4-11B). These data indicate that a partial block to reverse transcription occurred
after virus binding and internalization into 293/SSTR-2 and -3 cells, supporting the
interpretation that the endocytic pathway utilized by SSTR-5 directs virus to a more
permissive environment for penetration.
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Figure 4-10. SSTR-5 internalizes to a more permissive intracellular environment
A and B. 293, 293/SSTR-2,-3 and -5 or NIH 3T3 cells were pretreated with (A) DMSO, 5
µM or 25 µM CA074 Me or (B) H2O, 30 µg/ml or 100 µg/ml leupeptin prior to Sst-RBS,
VSV G or WT MLV exposure, as indicated, while maintaining the drug or vehicle.
Infection was scored with Romanizer software for the presence of β-galactosidase
positive cells at 48 hpi Relative infection was calculated as the percentage of infection
compared to the vehicle only treated cells. There was no observable infection of 293
cells in the presence or absence of CA074 Me or leupeptin.
All data represent the mean ± SD of at least three independent experiments (n=4). P
values were calculated by using two way ANOVA and Bonferroni posttest. **, p ≤ 0.01.
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Figure 4-11. Virus internalized via SSTR-5 more efficiently penetrates into the host
cytoplasm
A. Whole cell DNA was isolated from 293, SSTR-expressing and NIH 3T3 cells exposed
to Sst-RBS or WT MLV. DNA was isolated from cells incubated with virus at 4 °C but not
shifted to 37 °C and from replicate cell cultures 6 hours after a 37 °C shift to allow
internalization, membrane fusion and viral nucleocapsid penetration of the host cell
cytoplasm as indicated in the experimental time line.
B. Results obtained from the MSS and LacZ amplicons were normalized to the β-actin
signal for the respective host cell line and the fold increase in the level of reverse
transcription was calculated as a measure of virion penetration by comparing LacZ gene
amplification to the MSS amplification signal over the 6 hour time period. No
amplification was detected in mock-infected cells.
Each symbol represents the relative fold increase in pseudovirion penetration from one
independent experiment. The mean relative fold increase from six independent
experiments is shown below the graph (n=3). P values were calculated using one way
ANOVA and Dunn’s posttest. **, p ≤ 0.01.
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Discussion
This chapter reports observable differences in the level of infection of Sst-RBS
pseudotyped retroviruses when exposed to 293 cells stably expressing somatostatin
receptor subtypes 2, 3 and 5 (Figures 4-2A and B) that correlate with distinctive
receptor subtype-specific characteristics. When facilitated by SSTR-2 and -3, infection is
restricted at a point after receptor binding and internalization (Figures 4-5 and 4-6B) but
prior to penetration into the host cytoplasm (Figure 4-11). In contrast, SSTR-5 mediated
entry featured slower internalization with characteristics similar to that observed for WT
MLV (Figures 4-7 and 4-8). Virus bound to SSTR-5 was directed to an intracellular
environment that allowed near WT levels of penetration (Figure 4-11) possibly due to a
more favorable complement of host cell proteases (Figure 4-10).
Taken together I interpret these results to support that the observed differences in
infection between SSTR subtypes are primarily due to differences in the fate of
internalized virus-receptor complexes. I favor that the intracellular trafficking patterns
accessible to each subtype impose constraints on internalized virus-receptor complexes
and direct viruses to more, or less, permissive environments. Figure 4-12 shows a
model of virus entry illustrating these observations and the proposed pathways used by
the SSTR subtypes. This interpretation is consistent with reports of agonist-induced
SSTR desensitization (natural ligand removal and receptor recycling or degradation).
While SSTR-2, -3 and -5 are similar in structure, kinetics of agonist binding and
internalization [30], the subtypes differ in their intracellular trafficking during
agonist-induced desensitization. SSTR-5 lacks the clusters of Ser/Thr phosphate
acceptor sites found on the cytoplasmic tails of subtypes 2 and 3 [30, 34, 77]. These
clustered phosphate acceptor sites have been shown to control the intracellular
destination of ligand-SSTR complexes by regulating β-arrestin and scaffolding protein
recruitment to endocytic vesicles resulting in distinct intracellular fates for the
internalized ligand-receptor subtype complexes [30, 36, 77].
Inhibition during virus binding and internalization would represent relatively trivial
explanations for the different levels of infection observed among the somatostatin
subtype expressing cell lines; whereas effects on fusion and penetration are of greater
interest. A standard virus binding assay was unable to detect Sst-RBS MLV binding to
any of the SSTR subtypes that was above the level of binding to control 293 cells, and
the relative amount of cell-associated virus was similarly uninformative (Figure 4-5).
However, there was an extremely large difference in the LacZ transducing units between
SSTR-2 and SSTR-5 (222 fold, Figure 4-2). If this were due to a higher percentage of
virions binding and internalizing in 293/SSTR-5 cells it is likely that that either the
standard binding and/or the more sensitive quantitative real-time PCR assay would
reflect this. Instead, it is possible that these data reflect non-specific binding [78] and
endogenous SSTR-2 receptor expression in 293 cells [79] which, under the typical
infection conditions used in this study, do not permit transduction. However, transduction
in 293 cells was enhanced under the same conditions as 293/SSTR-2 (see Figure 4-9
legend) indicating that binding and internalization does occur in 293 cells and low levels
of infection can be detected under neutralizing conditions. For this reason the amount of
cell-associated virus was normalized to account for virus that may be associated with the
SSTR expressing cell lines because of their 293 parentage. When these data are
expressed as the fold increase compared to the amount of cell-associated virus in the
293 cells no differences amongst the cell lines were observed that can account for the
increased transduction via SSTR-5.
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Figure 4-12. Model of the influence of intracellular destination on infection
Thick arrows indicate that comparable amounts of Sst-RBS pseudotyped virus are
internalized by each SSTR subtype. Thin arrows indicate that a large percentage of
virions complete penetration, reverse-transcription and integration when internalized via
SSTR-5. Dashed arrows indicate that a relatively small percentage of virions internalized
via SSTR-2 and -3 complete critical late steps of entry into the host cell cytoplasm for
infection. The infection characteristics observed for each SSTR subtype are listed next
to the corresponding entry pathway.
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If Sst-RBS LV pseudovirions had shown comparable levels of infection among the
cell types despite the fact that the MLV pseudotypes were divergent, then this would
suggest that the critical step in infection of these virions was dependent on the core
particle or genome of the virus (Figure 4-2). On the contrary, these data strongly
indicate that the differences in infection are envelope dependent. Since the Sst-RBS
glycoprotein is the same in both the LV and MLV pseudovirions and infection was
competitively inhibited in each of the SSTR expressing cell lines, the receptor subtype is
the most likely variable that could affect such an influence.
Multiple lines of evidence presented here indicate that Sst-RBS pseudovirions
internalized via SSTR-5 utilize a distinct intracellular trafficking pattern from that used by
SSTR-2 and 3. First, although each of the SSTR-expressing cell lines displayed a
dependence on host cell cholesterol for endocytosis, transduction via SSTR-5 was as
sensitive to MβCD cholesterol depletion as infection of WT MLV via mCAT-1 on NIH 3T3
cells (Figure 4-6C) in which mCAT-1 co-localizes with caveolin during internalization [5].
Second, Sst-RBS pseudovirions internalized at a slower rate in 293/SSTR-5 cells than in
the SSTR-2 and -3 lines (Figures 4-7 and 4-8). Third, infection of 293/SSTR-2 and -3
cells increased significantly in the presence of BafA and monensin, whereas infection of
293/SSTR-5 cells was not affected by these inhibitors of vesicular acidification (Figure
4-9A and C). In accordance, HIV-1 infection has been shown to increase in the presence
of BafA, an effect that the authors attributed to inhibition of lysosomal acidification that
slowed the degradation of virus particles to allow more time for membrane fusion [65].
Viejo-Borbolla and coworkers also proposed a similar explanation for their finding that
infection of a modified Moloney MLV glycoprotein retaining the use of mCAT-1 was also
increased in the presence of BafA [80].
While I favor that the entry pathway used by Sst-RBS MLV bound to SSTR-2 and -3
exposes virions to a more destructive set of proteases than those entering via SSTR-5, it
is also possible that the acidic nature of these compartments may influence the structure
of the Env glycoprotein making it more susceptible to inactivation by cellular proteases
or less attractive to proteases involved in activating membrane fusion. The extent to
which leupeptin inhibited infection of 293/SSTR-2 and -3 cells (Figure 4-10B) indicates
the importance of lysosomal proteases in these entry pathways. The parasitic nature of
viruses, in particular those such as MLV that rely on host proteases to potentiate the
conformational changes required for efficient entry (in contrast to those like VSV whose
requirements rely strictly on acidic pH), means that they walk a fine line between
potentiation and degradation by these same proteases. Raising the pH of intracellular
compartments requires the proteases to function sub-optimally and shifts the dynamic to
favor virus entry instead of degradation. However, leupeptin directly inhibits these
lysosomal proteases revealing that they are indeed responsible for the results observed
in this study. The observation that lysosomal proteases do not appear to be involved in
infection via SSTR-5 is further evidence that this receptor delivers virions to a more
permissive compartment because it lacks degradative enzymes. The redundant nature
of these proteases, limited specificity of available inhibitors and lack of viable knock-out
cell lines make it difficult to determine exactly which protease is acting on virus
internalized by SSTR-2 and -3. However, possible candidate proteases are most likely in
the same class of cysteine proteases as cathepsin B, such as the lysosomal proteases
cathepsin H and cathepsin L1 since transduction in the presence of the inhibitor
CA074 Me showed similar levels of inhibition among the SSTR-expressing cells (Figure
4-10A). Regardless, the results of the drug and protease inhibitor studies, along with the
differing rates of internalization during early entry, are consistent with SSTR-2 and -3
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rapidly directing virus to a degradative compartment. In contrast, the patterns observed
for SSTR-5 suggest that it internalizes into a non-acidic environment (unaffected by
BafA) where it might persist for a longer period of time.
Several alternative interpretations were ruled out for the reasons stated below. First,
the increased titer might be explained if SSTR-5 allowed membrane fusion to occur at
the cell surface. A precedent for MLV surface fusion was established in rat XC sarcoma
cells [81] in which WT-MLV infection was shown to occur independently of microtubule
polymerization [43]. However surface fusion is unlikely in 293/SSTR-5 cells since
nocodazole inhibited infection indicating that microtubule polymerization is involved
(Figure 4-6B), a trait common to most endocytic mechanisms [55]. A second alternative
might be that the comparable levels of cell surface receptors detected by flow cytometry
using the HA epitope tag did not reflect the actual quantity available to bind virions nor
their capacity for internalization. For example, when SSTR-5 was exogenously
expressed in COS-7 cells, ligand binding resulted in internalization but surface SSTR-5
was quickly replenished by a combination of mobilization from intracellular pools and
receptor recycling [37]. In addition, if the exogenous expression of receptors in 293 cells
resulted in a stochastic limitation of the endocytic adaptor proteins, then the capacity of
subtypes 2 and 3 for internalization could be compromised. If either condition occurred
then a significant difference in the quantity of cell-associated and internalized virions
would be expected between the subtypes. However, quantitative real-time PCR of the
MSS DNA revealed that similar quantities of Sst-RBS pseudovirions associated with
293/SSTR-2, -3 and -5 cells during a 6 hour exposure (Figure 4-5C), supporting the
interpretation that the quantity of effective receptors and their capacity for internalization
were comparable amongst the subtypes.
Previous studies suggested that the internalization pathway can influence infection
of enveloped and non-enveloped viruses. Under normal conditions, ASLV-A infection is
equally efficient using the glycosylphosphatidylinositol (GPI)- and transmembraneanchored isoforms of its cellular receptor TVA [68] and viruses traffic to the same
intracellular compartment [69]. However, prolonged exposure of host cells to ammonium
chloride alters infection, reducing it for both receptor isoforms but to different degrees,
resulting in infection that is relatively greater using GPI-anchored TVA than the
transmembrane-anchored isoform [68]. In this perturbed system, viruses were trafficked
to different intracellular compartments that were apparently less permissive than the
compartment to which the virus normally traffics [69]. However, the ammonium chloridetreated cells showed abnormal intracellular compartment morphology and altered
subcellular localization of vesicular trafficking proteins [69] leaving open the question of
how much of the observed differences were relevant to natural infection as versus due to
pleiotropic effects of the prolonged exposure to ammonium chloride. Other evidence
comes from studies of rotaviruses. Strains of these non-enveloped viruses use a number
of different cellular receptors, with the choice of receptor being specified by differences
in the VP4 spike protein. Interestingly, a study of the strain-specific diversity of VP4
revealed a strong bias toward use of receptors that internalize by clathrin-mediated
endocytosis [82]. However, this study did not address if receptors using this endocytic
pathway delivered viruses to the same compartment or if the clathrin-dependent bias
could have evolved because this pathway is more productive for rotaviruses.
I examined the early entry stages of infection in an effort to more concisely
investigate if the intracellular trafficking of internalized virus-receptor complexes affected
the efficiency of infection. These studies were begun by generating a set of cell lines that

47

provided a system in which the predominant influence on infection would be differences
in intracellular trafficking of internalized virus-receptor complexes, thereby circumventing
the major technical constraints that have limited previous studies. Regardless of why the
intracellular destination varied between receptor subtypes, one subtype delivered virus
to a distinct compartment from which a significantly higher percentage of virions
penetrated into the host cell cytoplasm. The results directly demonstrate that the
intracellular trafficking pathways of a virus receptor can have profound effects on the
level of infection. Furthermore, opportunities for more efficient infection presented by
intracellular trafficking to more, or less, permissive intracellular environments exerted
selective pressure on the choice of a cellular protein as a receptor during viral spike and
glycoprotein evolution.
The notion that retroviral glycoproteins and their cellular receptors co-evolved is
significant when developing targeted viral vectors. The conformational changes of the
Env glycoprotein that are required to initiate infection likely occur only under conditions
that mimic the natural virus-receptor relationship. This implies that the placement and
structure of the targeting ligand within the glycoprotein are important, but it also suggests
that the choice of the targeted receptor should also be carefully considered. This
research indicates that targeting to a receptor which internalizes to an intracellular
destination with similar properties as the destination of the natural virus-receptor
complex will allow for the highest transduction capacity.
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Chapter 5. In Vivo Gene Transduction with Sst-RBS Pseudotyped Lentivirus§
Introduction
The capacity to transduce cells endogenously expressing SSTRs in vivo is the next
logical step in characterizing the Sst-RBS glycoprotein for use as an in vivo vector. The
brain was chosen as the target tissue for these studies because of its immunologically
privileged status ensuring that immune responses to the viral vectors would be restricted
in the immunocompetent subjects. Additionally, effective treatments have been difficult
to attain for the neurodegenerative symptoms of diseases such as the well-known
Alzheimer’s disease (AD), Huntington’s disease (HD) and Parkinson’s disease (PD)
since drug compounds only mask symptoms and fail to address the underlying causes of
these diseases. A related group of diseases which lack treatment for neurodegenerative
effects are lysosomal storage diseases (LSD) such as Mucopolysaccharidosis (MPS) VII
which results from a deficient β-glucuronidase (GUSB) enzyme. The deficiency leads to
an accumulation of glycosaminoglycans in lysosomal compartments. Affected individuals
develop pathologies such as organomegaly, progressive skeletal abnormalities and
neurological and cognitive dysfunctions [83] ranging in severity depending on the nature
of the enzyme deficiency [84]. Protein and enzyme replacement therapies (ERT), while
effective for treating the systemic progression of disease, have had no effect on
neurological symptoms due to the extremely limited ability for these treatments to cross
the blood brain barrier (BBB) and gain access to the central nervous system (CNS) [8587]. These reasons make neurodegenerative diseases good candidates for treatment
with lentiviral directed gene therapies.
SSTR are present in several regions of therapeutic interest in the brain including the
choroid plexus (ChP), ependymal cells lining the ventricular system, dentate gyrus of the
hippocampus (DG), corpus striatum, substantia nigra and subthalamic nucleus in the
brain [88, 89] and therefore should be capable of transduction by Sst-RBS pseudotyped
lentivirus particles. These regions would also be susceptible to transduction via VSV G
pseudotyped vectors but its broad tropism might actually be detrimental in the treatment
of these diseases. While it may seem reasonable to use a vector with the ability to
transduce nearly all the cells it encounters; this activity works more like a sponge,
soaking up large quantities of available vector, preventing its dispersal. In practice, a
large area of partially transduced cells may be preferable. Several studies delivering
GUSB to brain cells of deficient mice indicate that direct transduction of the GUSB gene
to all cells was not required to provide sufficient therapeutic benefit; as disease reversal
was observed even in non-transduced cells [90, 91]. The following study is an
investigation into the feasibility of in vivo delivery and a comparison of the ability of
Sst-RBS and VSV G pseudotyped virions to disperse into the brain parenchyma.
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Adapted with permission. Li, F., B. Y. Ryu, R. L. Krueger, S. A. Heldt and L. M.
Albritton.Targeted entry via somatostatin receptors using a novel modified retrovirus
glycoprotein that delivers genes at levels comparable to those of wild-type viral
glycoproteins. J Virol, 2012. 86(1): 373-381.
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Results
Proof of Principle for In Vivo Gene Transduction by Sst-RBS Pseudotyped
Lentivirus Particles
A pilot assay to determine the feasibility of intracranial delivery was performed by
microinjecting 2 µl of a concentrated stock of HIV-based SIN lentiviral vector bearing
either Sst-RBS or VSV G glycoproteins and transducing the red fluorescent protein
mKate2 into the subthalamic nucleus of one hemisphere of two mice. Three days post
injection the brain tissue was harvested and 20 µm frozen coronal sections were
analyzed at a magnification of 200X for the presence of mKate2 fluorescence. No red
fluorescence was observed in hemispheres that did not receive an injection in either the
Sst-RBS or VSV G LV exposed mouse (Figure 5-1A). In the contralateral hemisphere of
the VSV G LV injected mouse, numerous red fluorescing mKate2-transduced cells were
present along the lower length of the injection pathway or “needle track” (Figure 5-1B).
In contrast, the same length of needle track in the Sst-RBS LV injected mouse showed
very few red fluorescent cells but a burst of transduction was observed at the end of the
needle track in the region of the SN (Figure 5-1C). The area directly above the SN is
reportedly negative for SSTR expression [88, 89, 92], however the cellular receptor
recognizing VSV G is present throughout these regions [93]. This provides proof
principle that Sst-RBS LV does indeed transduce murine brain cells and may represent
targeted transduction of SSTR positive cells since a majority of red fluorescence was
observed at the end of the needletrack in a region reported to express SSTR [88] while
VSV G LV transduced cells in both SSTR expressing and non-expressing regions. The
level of transduction observed in the VSV LV injected mice was dramatically higher even
in the SN region. This was to be expected since these lentiviral stocks displayed an
approximate 200-fold difference in luciferase TU/ml (Figure 3-1). Based on these
observations, the concentrated VSV G LV stock was diluted 100 fold in PBS prior to
injection in subsequent experiments.
SSTR-2 Expression in the Murine Brain
Historically, investigations into the expression of SSTR in the rat and mouse brain
have been confined in situ hybridization to localize SSTR subtype mRNA expression or
autoradiography using radiolabeled synthetic ligands [88, 92]. More recently, rat models
have been used to directly address the level of SSTR surface expression in brain cells
with subtype specific antibodies [89]. In an effort to determine where in the mouse brain
SSTR surface expression is located, coronal sections were co-stained with a rabbit
monoclonal antibody to SSTR-2 and a mouse monoclonal antibody to the neuronal cell
nuclear membrane protein, NeuN. Several areas of positive SSTR-2 staining were
immediately evident and corresponded to previous reports. These areas were the
cerebral cortex layers IV, V and VI; the caudate putamen which comprises the corpus
striatum in the mouse; the ependymal cells lining the lateral and third ventricles (Figure
5-2A); the dentate gyrus of the hippocampus and the medial habenula (Figure 5-2B).
Sections were evaluated for co-expression of SSTR-2 and NeuN at a higher
magnification (200X). In the cortex (Figure 5-3A) and striatum (Figure 5-3B and 5-3C)
the SSTR-2 positive cells co-stain with the NeuN neuronal marker, however not all NeuN
positive cells co-stain with SSTR-2 suggesting that, while neurons are the
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Figure 5-1. Proof of principle for in vivo gene transduction by Sst-RBS
pseudotyped lentivirus
Phase contrast images and corresponding mKate2 fluorescence of the uninjected (A) or
injected (B and C) hemispheres of mice exposed to VSV G or Sst-RBS lentivirus
transducing mKate2. The coronal murine brain section and arrow to the left is presented
to indicate the injection trajectory of the representative micrographs at the right. Tissue
sections from 9-12 week old mice were microinjected with 2 µl of Sst-RBS or VSV G
pseudotyped LV transducing the red fluorescent protein marker, mKate2, in the
subthalamic nucleus. Three days later mice were sacrificed and 20 µm frozen coronal
sections imaged at 200X magnification on a Zeiss Deconvolution microscope. Multiple
image frames were carefully aligned to provide a complete image of the needle track.
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Figure 5-2. SSTR-2 receptors are expressed in the murine brain
A and B. Coronal sections through the septo-diencephalic (A) and rostral diencephalic
(B) regions from 9-12 week old mice were co-stained with Hoechst nuclear stain (blue),
monoclonal mouse anti-NeuN neuronal marker and goat anti-mouse Alexa-647 (purple),
monoclonal rabbit anti-SSTR2 and goat anti-rabbit Alexa-488 (green). Micrographs were
imaged by Aperio ScanScope at 6X magnification. SSTR-2 positive regions of interest
labeled: CC, Cerebral Cortex; CP, Caudate Putamen of the Corpus Striatum; LtV,
Lateral Ventricle, DG, Dentate Gyrus of the Hippocampus H, Habenula (medial).
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Figure 5-3. SSTR-2 receptors are expressed on neurons of the murine brain
A, B and C. Some, but not all, cortical (A) and striatal (B-C) cells co-stain with the
neuronal marker NeuN and surface expression of SSTR-2. Coronal murine brain
sections and white boxes to the left are presented to indicate the area from which the
micrographs at the right were taken. 20 µm frozen coronal sections from 9-12 week old
mice were co-stained with Hoechst nuclear stain (blue), monoclonal mouse anti-NeuN
and goat anti-mouse Alexa-594 (red), monoclonal rabbit anti-SSTR-2 and goat antirabbit Alexa-488 (green). Micrographs were imaged on a Zeiss Deconvolution
microscope at 200X magnification.
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primary cell type expressing SSTR-2 in these areas, only certain neuronal types do so.
Interestingly, the ependymal cells lining the lateral (Figure 5-4A) and third ventricles
(Figure 5-4B) also express SSTR-2; however, ependymal cells are of a glial lineage.
They stain positively for glial fibrillary acidic protein (GFAP) and do not express NeuN
[94]. Co-staining sections with antibody recognizing the GFAP and SSTR-2 was not
possible during the course of these studies because both primary antibodies were
produced in rabbit hosts. Therefore it is possible that other cells of glial lineage may also
express surface SSTR-2.
Sst-RBS Lentivirus Mediated Transduction in the Murine Brain
The lateral ventricle of a mouse injected with 2 µl of concentrated Sst-RBS LV
vector was evaluated for the presence of mKate2 transduction in cells expressing
surface SSTR-2. The injection trajectory of this mouse was originally intended to target
the striatum, not the area surrounding the ventricle. However, the variable nature of
working with individual subjects is such that this particular injection was sufficiently close
to the ventricle that transduction was observed in SSTR-2 expressing cells in the region
of the lateral ventricle. This included the NeuN negative ependymal cells (Figure 5-5).
Transduction was also observed in the striatum of mice injected with 2 µl of
approximately equal luciferase transducing units of Sst-RBS LV or VSV G LV.
Representative images of mKate2 transduction along the needle-tracks of both vectors
are shown in Figure 5-6A and B. VSV G LV mediated mKate2 transduction was
observed to be heavily concentrated around a central core with little diffusion into the
surrounding area. In contrast, the core transduction of Sst-RBS LV was less dense but
larger in overall area; suggesting that the Sst-RBS LV vector possessed a greater
capacity for diffusion in this region of the brain. The area of mKate2 transduction from
three Sst-RBS and VSV G LV injected mice was determined using Image J software
analysis. The mean area of mKate2 transduction did not differ significantly between the
mice injected with Sst-RBS or VSV G pseudotyped vectors, indicating that Sst-RBS
pseudotyped lentiviral vectors have a comparable transduction capacity as VSV G
vectors in vivo.
The transduction zones (TZ) of multiple sections from three mice injected with 2 µl
of either the Sst-RBS or VSV G pseudotyped LV vectors were quantified by measuring
the height and width of the core and maximum TZ and calculating the ellipsoidal area.
The core TZ was defined as the area with the highest concentration of mKate2
expression and the maximum TZ as the largest overall area of mKate2 expression.
Additionally, transduction from the contralateral hemisphere of each mouse was
measured. These hemispheres were injected with 2 µl of either Sst-RBS or VSV G LV
vectors immediately after the injection of 0.5 µl of 100 µM SST-14 peptide, which inhibits
Sst-RBS but not VSV G mediated transduction (Figure 4-3). The mean core
measurements of both Sst-RBS LV exposed hemispheres were comparable as were the
core measurements of the VSV G treated mice in the presence and absence of the
peptide. Interestingly, the mean Sst-RBS core TZs were larger than the VSV G cores
(Figure 5-7A to E). When the maximum TZs were measured, the untreated Sst-RBS
and VSV G zones were comparable in size, but the mean TZ of the hemispheres
pre-treated with SST-14 prior to Sst-RBS LV exposure were slightly smaller than their
untreated counterparts. As expected, SST-14 pre-treatment had no effect on the
maximum TZ area of VSV G (Figure 5-7F to J). Even though this was a small sample
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Figure 5-4. SSTR-2 receptors are expressed on murine ependymal cells
A and B. Ependymal cells lining the lateral (A) and third ventricles (B) of the murine brain
do not stain positively for the neuronal marker NeuN, but express the SSTR-2 receptor.
Coronal murine brain sections and white boxes to the left are presented to indicate the
area from which the micrographs at the right were taken. 20 µm frozen coronal sections
from 9-12 week old mice were co-stained with Hoechst nuclear stain (blue), monoclonal
mouse anti-NeuN and goat anti-mouse Alexa-594 (red), monoclonal rabbit anti-SSTR-2
and goat anti-rabbit Alexa-488 (green). Micrographs were then imaged on a Zeiss
deconvolution microscope at 200X magnification.
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Figure 5-5. Sst-RBS lentivirus mediated transduction of murine ependymal cells
SSTR-2 positive murine ependymal cells colocalize with Sst-RBS-mediated mKate2
marker transduction. The coronal murine brain section and red arrow to the left is
presented to indicate the injection trajectory of the representative micrographs at the
right. Tissue sections from 9-12 week old mice were microinjected with 2 µl of Sst-RBS
pseudotyped lentivirus transducing the fluorescent protein marker mKate2 (red) in the
caudate putamen. Three days later mice were sacrificed and 20 µm frozen coronal
sections co-stained with monoclonal rabbit anti-SSTR-2 and goat anti-rabbit Alexa-488
(green) and monoclonal mouse anti-NeuN and goat anti-mouse Alexa-647 (purple).
Micrographs were imaged by Aperio Scanscope at 50X and 200X magnification.
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Figure 5-6. Sst-RBS and VSV G lentivirus mediated transduction along the
needle-tracks in the striatum of mice
A, B and C. Representative mKate2 (red) transduction zones from Sst-RBS (A) or VSV
G (10-2 TU/ml) (B) pseudotyped lentivirus microinjected into the caudate putamen of 912 week old C57bl/6 mice. Three days later mice were sacrificed and 20 µm frozen
coronal sections were stained with Hoechst nuclear stain (blue) and micrographs imaged
by Aperio Scanscope at 34X magnification. (C) The area of mKate2 transduction from
three Sst-RBS LV (purple) or VSV G LV (white) injected mice was determined using
Image J software. The mean and SD of mKate2 transduction is shown (n=3).
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Figure 5-7. Transduction zone diffusion of Sst-RBS and VSV G lentivirus
particles in intracranially injected mice
A through L. Mice were microinjected in the caudate putamen with 2 µl of concentrated
mKate2 transducing lentivirus coated with Sst-RBS or VSV G (10-2 TU/ml) in the
presence or absence of 100 µM SST-14 ligand. Three days post infection, the mice were
sacrificed, and 20 µm frozen tissue sections were analyzed for mKate2 expression (red).
Aperio Scanscope images were measured for core (A-E) and maximum (F-J)
transduction zone areas. The mean ± SD for three mice are shown in A and F.
Representative images for Sst-RBS (B,C, G, H) and VSV G (D,E,I,J) zones are shown
indicating mKate2 expression as well as areas of no transduction from comparable
sections for Sst-RBS (K) and VSV G (L).
One Way ANOVA and Bonferroni posttest used to determine P-value > 0.05; NS, Not
Significant.
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size (n=3), some guarded conclusions could be drawn from these observations. First,
the larger core TZ area of Sst-RBS LV suggests that it was capable of diffusing away
from the injection site into the surrounding brain tissue while the VSV G LV particles
were immediately adsorbed onto cells in the vicinity of the injection site. Second, the
comparable maximum TZs of hemispheres exposed to virus in the absence of SST-14
suggest that VSV G LV particles escaping adsorption at the injection site were capable
of diffusing the same distance as Sst-RBS LV particles. In general, however, the VSV G
TZs had a more distinct core and less distinct maximum area; whereas, the Sst-RBS
TZs were more uniform in intensity throughout both measurement areas. Third, the
decrease in maximum TZ area of Sst-RBS LV in the presence of SST-14, although not
statistically significant, can be interpreted to indicate that transduction was specifically
mediated by the presence of SSTR.
Discussion
This study demonstrated proof of principle for in vivo Sst-RBS mediated
transduction in the murine brain (Figure 5-1) which displayed comparable transduction
efficiency to VSV G pseudotyped vectors (Figures 5-6 and 5-7). Several regions of
interest in the murine brain stain positively for SSTR-2 surface expression (Figure 5-2)
and SSTR-2 is expressed on some classes of neurons (Figure 5-3) as well as
ependymal cells which line the ventricular system (Figures 5-4 and 5-5). These
observations suggest several areas of potential clinical relevance for the chimeric SstRBS glycoprotein. The subthalamic nucleus is involved in PD and has also been
implicated in AD [95]. Additionally, transduction of cells in the striatum indicates that this
new chimeric glycoprotein may be useful as a therapeutic and investigational tool for AD
and HD as well as other neurodegenerative diseases involving these regions of the brain
such as LSDs.
Enzyme replacement therapies (ERT) have been developed for several LSDs
including Gaucher disease, Fabry disease, Pompe disease, MPS I, MPS II and MPS VI
[86, 96] based on the discovery that a small amount of proenzyme is naturally excreted
during transport from the TGN to lysosomes and can be taken up either by the original or
a neighboring cell by the mannonse-6-phosphate receptor (M6PR) [97, 98]. However,
with the exception of Gaucher disease [86, 99], ERT has only been moderately
successful since it requires life-long treatments of exogenously produced recombinant
enzymes [87] and because intravenously administered enzyme is inefficiently delivered
to target cells. A majority of recombinant enzymes collect in reticuloendothelial cells of
the liver and spleen [86] and are incapable of crossing the BBB for delivery to the CNS
[86, 96]. The latter is a particular concern for LSDs that manifest with severe
neurodegeneration such as MPS VII. Directly injecting enzyme into the cerebrospinal
fluid (CSF) may be a means of circumventing the BBB, but this approach still remains
impractical due to the long-term nature of ERT [86].
Advances in gene therapy are a promising direction for the treatment of neurological
diseases and LSDs. Both systemic and direct CNS delivery of viral vectors including
adenovirus (ADV), adeno-associated (AAV), RV and LV vectors have successfully
transduced target genes providing long-term protein expression (for review see [96]).
RVs and LVs are particularly useful due to their ability to integrate into host
chromosomes thus alleviating the continious nature of ERT. Typically, intravenous
delivery of GUSB expressing vectors results in transduction of liver and spleen cells
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which are then capable of secreting enough cross-protective enzyme into the
bloodstream that therapueutic benefits were observed in the peripheral organs and
skeleton [100-103]; however, transport across the BBB is not evident [96, 100, 102]. In
contrast, direct injection into the CNS has been shown to be effective at long term
expression of marker and therapeutic genes by ADV, AAV and VSV G pseudotyped RV
and LV delivery methods [90, 91, 96, 104]. While ADV, AAV and LV particles were
capable of transducing both NeuN postive neurons and GFAP postive glial cells (VSV G
pseudotyped RV was not capable of transducing the terminally differentiated neurons),
VSV G pseudotyped LV was by far the most efficient. The LV transduced more
cells/mm3 than the other vectors with approximately 89% of all transduced cells identified
as NeuN positve neurons [105]. The present study suggests that the Sst-RBS targeting
LV is at least as capable of trandsduction as the VSV G LV when approximately equal
TU/ml were compared (Figure 5-7F). Moreover, the Sst-RBS LV may be preferrable.
Due to its targeted nature it displayed a greater potential for diffusion away from the
initial injection site (Figure 5-7A).
SSTR mRNA and surface expression have been demonstrated throughout the
murine and rat brain. Whereas SSTR-2 and -3 are the predominant subtypes expressed,
SSTR-1 and -4 are also expressed and to a far lesser extent SSTR-5. [88, 89, 92]. This
study only investigated the expression of SSTR-2 in the murine brain as an initial
indication of feasibility. Since the SST-14 ligand displayed by the Sst-RBS glycoprotein
is equally capable of binding and internalizing through subtypes 2, 3 and 5 (Figure 4-5),
transduction might occur via any of the SSTR subtypes in vivo.
It was surprising to note that Sst-RBS mediated transduction was as efficient in vivo
as VSV G (Figure 5-6) given that SSTR-5 expression in the brain is reportedly extremely
low and in vitro transduction was significantly greater via this subtype than SSTR-2 and3 (Figure 4-2), the predominant subtypes expressed in the brain [88, 89]. This suggests
that, at least in the brain, in vitro studies may not correlate with in vivo transduction.
Since the presence of only one SSTR subtype, SSTR-2, was evaluated during this
preliminary investigation; this level of Sst-RBS mediated transduction might represent
the use of several SSTR subtypes as multiple SSTR expression has been reported [88,
89]. Further studies will need to be performed in order to assess the expression of each
SSTR subtype in lentivirus transduced brain cells. Additionally, the highly specialized
nature of neurons may further account for this disconnect. Their unique shape and size
means that their intracellular trafficking patterns are prolonged compared to other cell
types [106, 107]. Moreover, their low turn-over rate, limited access to extracellular
nutrients and need to heavily regulate their membrane and cytoplasmic contents set
extreme limits on cellular resources. One of the many ways neurons have developed to
compensate for these requirements is a highly ordered endosomal and lysosomal
system. [106-108]. Indeed, the lysosomal compartments of neurons are exquisitely
sensitive to perturbation as evidenced by their involvement in almost every
neurodegenerative disease including those discussed above. In an effort to conserve
resources, neuronal cells often slowly recycle signaling receptors such as SSTRs
instead of downregulating them through lysosomal degradation [107, 108]. In agreement
with this, Csaba and colleagues demonstrated retrograde transport and recycling of
SSTR-2 in hippocampal neurons. Agonist induced SSTR-2 internalization was achieved
through rapid endocytosis to early-endosomes, bypassing the low pH compartments it
accumulated in a perinuclear region consistent with the TGN before slowly recycling
back to the plasma membrane [109]. Evidence that trafficking to acidic environments
inhibited transduction in 293/SSTR-2 and -3 cells (Figure 4-9) supports that the
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neuronal SSTR-2 trafficking pathway might provide a higher level of transduction than in
in vitro systems. Additionally, the elongated intracellular route that the virus-SSTR
complex travels may provide the time necessary for membrane fusion and penetration
events to occur.
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Chapter 6. Discussion
Identify the Endocytic Mechanisms and Intracellular Destination of Sst-RBS Entry
In this body of work I demonstrated that MLV and HIV-1 based virion particles
pseudotyped with the Sst-RBS glycoprotein were trafficked to at least two different
intracellular compartments in 293 cells expressing SSTR subtypes 2, 3 and 5. Moreover,
the intracellular environment to which SSTR-5 was directed was more permissive than
the environment that SSTR-2 and -3 directed viruses. This investigation into receptor
characteristics is significant in that it directly demonstrates that differences in virusreceptor trafficking can profoundly influence infection efficiency. Endocytosis of the
somatostatin receptor subtypes 2, 3 and 5 has previously been shown to be clathrindependent [28, 37]. Yet several lines of evidence suggest that virus bound to SSTR-5
was internalized by a distinct mechanism than SSTR-2 and -3; moreover, this functional
difference in endocytosis directly correlated with a higher level of infection. Further
experiments to address which endocytic mechanism Sst-RBS uses for internalization via
these receptors, identify which intracellular locations these virus-receptor complexes are
directed and how they influence virus entry would be beneficial for a complete
characterization of Sst-RBS mediated entry; as well as determining how useful particular
endocytic and intracellular pathways may be to targeting gene delivery.
To further investigate the endocytic mechanism of Sst-RBS mediated entry,
dominant negative (DN) Rab GTPases can be utilized. Rab proteins are members of the
Ras GTPase superfamily and are the master regulatory elements of endosomal
transport and vesicular trafficking within cells. They act as guanine nucleotide-dependent
switches which further recruit cascades of effector molecules [110, 111]. Together these
mechanisms sort cargo, control the directionality of vesicle movement and govern
membrane fusion between vesicles [112]. Over 60 Rabs have been identified in humans
thus far [112]. Rab5, Rab7 and Rab11 especially, have been extensively studied for their
pivotal roles in endocytosis and have become the defining markers for the early (EE),
middle/late (LE) and recycling (RE) endosomes, respectively. Cells transiently
expressing a DN-Rab5 protein have been shown to be defective for fusion of primary
endocytic vesicles from the plasma membrane with the EEs, and DN-Rab7 prevents the
fusion of EEs and LEs blocking the pathway to lysosomes. Recently Rab11 depletion
was shown to inhibit the fusion of REs with the plasma surface [113]. Whereas Influenza
A virus infection was inhibited by the expression of both DN-Rab5 and DN-Rab7
(indicating the involvement of the LE) infection of VSV and Semliki Forest virus were
only inhibited by DN-Rab5 expression indicating the involvement of only the EE
compartment for these two viruses [114, 115]. Additionally, DN-Rab11 had no effect on
infection of either Influenza or VSV viruses [114]. From these results I would predict that
Sst-RBS infection via each SSTR should be inhibited by DN-Rab5 expression; however,
would expression of DN-Rab7 increase infection via SSTR-2 and -3 by blocking the
degradative pathway? Also, if the RE is involved in increasing the effective number of
SSTR-5 receptors, an additional question that might be answered is would inhibiting the
recycling pathway with DN-Rab11 also inhibit infection via SSTR-5? To test these
questions, the SSTR-expressing cell lines would be transiently transfected with one of
the DN-Rab expression plasmids in which the Rab protein is fused with a GFP marker.
These cell populations (as well as populations transiently transfected with WT Rab
constructs fused to GFP) would then be exposed to Sst-RBS, WT and VSV G
pseudotyped MLV particles. At 48 hpi, when β-galactosidase expression is evident, the
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cells will be fixed and permeabilized. An anti-β-galactosidase antibody followed by a
secondary antibody conjugated to Alexa-594 will be used to probe for transfected cells
so that both GFP and β-galactosidase expression can be visualized simultaneously. At
least 100 hundred individual cells would then be evaluated for co-expression of GFP and
β-galactosidase. If transduction is inhibited by the loss of Rab activity, a decrease in the
number of cells that are both GFP and β-galactosidase positive will be observed
compared to the WT Rab transfected SSTR-expressing cells.
Dependence on the presence of Rab5 and Rab7 could also be used to investigate
the endocytic mechanism by which Sst-RBS-SSTR subtypes are internalized.
Clathrin-mediated endocytosis shows dependence on both Rab5 and Rab7 while
Caveolin-associated endocytosis only shows dependence on Rab5 [55]. Several
pathways in addition to clathrin- and caveolin-dependent endocytosis are utilized by
viruses for the purpose of gaining entry to the intracellular milieu. Of particular interest is
the macropinocytic pathway which typically involves microtubules, cholesterol, Rab5,
and Rab7 as well as other cellular processes like Na+/H+ exchange, which decreases
the pH of pre-lysosomal and lysosomal vesicles. A growing number of viruses have been
shown to be internalized in macropinosomes including vaccinia virus, adenovirus
serotype 3, echovirus 1, coxsackivirus B, herpes simples virus 1, and has been
implicated in HIV-1 infection [116]. Recently, ebola virus was also added to this list [117,
118]. If infection of Sst-RBS shows dependence on both Rab5 and Rab7 the use of a
phosphatidylinositol‑3-kinase (PI3K) inhibitor such as wortmannin to inhibit ruffle
formation might help distinguish clathrin-mediated from macropinosome internalization.
I demonstrated that there was a significant block to entry of Sst-RBS pseudotyped
virions via SSTR-2 and -3 which occurred after internalization but prior to reverse
transcription (Figure 4-11). A block of this type is often seen when virions fail to trigger
membrane fusion [12, 14, 46]. Membrane fusion of the WT MLV Env is accomplished by
first binding to its cellular receptor that, in turn, causes conformational changes between
the TM and SU subunits. Upon internalization, host cell proteases further potentiate
membrane fusion by cleaving the MLV Env, allowing conversion from a hemi-fusion to a
fusion state, which subsequently allows pore formation and virion core penetration [7, 8].
The Sst-RBS virus is capable of efficient membrane fusion when bound to and
internalized by SSTR-5, but are the possible fusion defects seen in 293/SSTR-2 and -3
cells because the correct TM-SU conformation changes were not achieved or because
the compartment to which these receptor subtypes direct the virions is non-permissive?
Evidence that virions bound to SSTR-2 and -3 were capable of inducing membrane
fusion was seen when infection was carried out in the presence of BafA and monensin
which neutralize endosomal compartments (Figure 4-9); indicating that the block is due
to the nature of the compartments. Direct demonstration that SSTR-2 and SSTR-3 are
fusion-competent can be achieved through a cell-cell fusion assay in which mixing of the
outer leaflet of the cell membrane is compared to cytoplasmic content mixing. Effector
293 cells exogenously expressing the Sst-RBS glycoprotein and a cytoplasmic dye are
mixed with target 293/SSTR-expressing cells containing a differently colored cytoplasmic
dye and DiI, a lipid soluble dye as a membrane marker. In previous infection
experiments, it was noted numerous times that 293/SSTR-expressing cells do not form
syncytia in the presence of Sst-RBS virus; however, the cells do show a higher order of
cell-cell attachment that is typically seen immediately prior to syncytia formation
(anecdotal evidence). These cell-cell attachments might indicate that the virus is trapped
in hemi-fusion state and incapable of completing membrane fusion because they have
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not been exposed to host proteases. If this is the case, one would expect some degree
of lipid mixing between the outer plasma membrane of DiI positive target cells and
negative effector cells. To induce membrane fusion and content mixing, a protease may
need to be added to the cells as a final trigger. Possible outcomes of this experiment
might indicate that each SSTR is capable of mediating the same amount of membrane
fusion after the protease trigger; or alternatively, that Sst-RBS-SSTR-5 complexes are
more fusigenic. Additionally, while the complexes may be triggered by the same
protease they might be sufficiently distinct that the protease that triggers the SSTR-5
complex is different from the protease required by SSTR-2 and -3. If the latter is true
then identifying which proteases are capable of triggering membrane fusion may also
provide clues to the intracellular location that each of these receptors directs internalized
viruses. Knowledge gained from this information would build a better foundation for
creating viral vectors that match the entry requirements of the targeted entry receptor.
Sst-RBS Lentivirus Titers
A particular unexplained observation was that while the Sst-RBS LV titers showed
the same general trend of transduction in vitro, namely that transduction of 293/SSTR-5
cells was higher than 293/SSTR-2 and -3 cells, the overall transduction of Sst-RBS LV
compared to the equivalently pseudotyped MLV was much lower (Figure 4-2). Yet this
does not seem to translate into low titers during in vivo experiments (Figure 5-6) in the
mouse brain. This might be due to a relatively low number of glycoprotein spikes
incorporated by the HIV-1 virion in its membrane. Typically, HIV-1 incorporates between
8-10 trimers per virion [119]. Others demonstrated that whereas low levels of Env
incorporation was sufficiently capable of mediating transfection, artificially enhancing the
amount of Env increased transduction but only to a certain extent [120]. Additionally,
retrovirus Env pseudotyped LV particles showed limited levels of incorporation [48, 49]
and transduction [23] which may also be a factor in decreasing the overall LV titers.
A further explanation may be that a host restriction factor is acting on either or both
the MLV and LV particles. Multiple host restriction factors have been identified and
characterized in humans, mice and non-human primates with varying restrictive activities
for retroviruses as well as a number of other viruses. Of the currently identified host
restriction factors, the most pertinent to the systems described in this research are the
APOBEC3, TRIM5α, Fv1 and the recently identified Tetherin and SAMHD1 proteins
[121]. Restriction of viruses by these host factors occurs by one or a combination of the
following: preventing virion budding, uncoating, reverse transcription of viral RNA, or
nuclear import/integration mechanisms.
APOBEC3 (Apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3)
proteins belong to the cytidine deaminase family. Humans encode 6 proteins (A, B, C,
DE, F, G and H) whereas mice encode a single protein. The mouse APOBEC3 protein
and the human G and F proteins can have restrictive activity on HIV-1 infection. They
are packaged into virus particles by producer cells and are transferred to target cells
during infection and inhibit viral replication by cytidine deaminase-dependent
or -independent mechanisms. In the dependent mechanism, viral cytosines are
deaminated to generate uracils on newly synthesized minus-strand cDNA. The presence
of uracils in DNA either triggers DNA repair enzymes to degrade the product or they
generate G to A hyper-mutations in the copied plus-strand DNA that negatively affect the
integrity of the viral genomic content [121, 122]. APOBEC3G and F can also reduce the
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efficiency of tRNAlys3 priming of the viral RNA and block reverse transcription as well as
block viral integration in deaminase-independent mechanisms that are not well
understood [121]. HIV-1 has developed an accessory protein; Vif (viral infectivity factor)
that is capable of binding APOBEC3 proteins and linking them to E3 ligases which
induces polyubiquitylation of both APOBEC3 and Vif triggering proteasomal degradation
[113, 114]. Vif is also capable of blocking APOBEC3 protein from encapsulation by an
unknown degradation-independent mechanism [121]. Thusly, APOBEC3G and F should
not be capable of restricting the Vif-positive HIV-1 infection in the human 293-derived
SSTR-expressing cell lines. Interestingly, Vif activity is species-specific; but HIV-1 Vif
should also be capable of blocking and counteracting APOBEC3G and F proteins during
the in vivo mouse experiments because their activity is entirely dependent on packaging
in virions prior to release. Since the producer cell line (293FT) used to generate the
Sst-RBS and VSV G pseudotyped LV particles for these experiments is a human line,
the species-specificity is still guaranteed. Additionally, human APOBEC3 proteins do not
restrict MLV viruses [122].
Tetherin is constitutively expressed on the surface of bone-marrow CD34+ cells as
well as B and T cells. It is an unusual membrane protein in that it is doubly anchored at
the cell surface by a glycophosphatidylinositol (GPI) anchor in cholesterol-rich lipid
microdomains and an α-helical transmembrane domain located outside lipid rafts.
Tetherin’s restrictive activity most likely derives from a homodimeric structure which
anchors budding virions via the GPI-anchor at virus assembly sites in lipid microdomains
and “tethers” them to the surface via the transmembrane domain inhibiting the release of
the budding virions. The HIV-1 accessory protein U (Vpu) is capable of binding to and
down-regulating tetherin from cell surfaces possibly by proteasomal degradation [121].
The recently described SAMHD1 (sterile alpha motif and histidine-aspartic domain)
protein is expressed in myeloid cells, T and B cells. It restricts HIV-1 and MLV replication
by decreasing the intracellular pool of dNTPs in non-dividing cells [121]. However, no
expression of either of these two host factors has been documented in human 293 cells
or murine brain cells.
The human tripartite motif (TRIM)-containing protein 5α isoform shows crossspecies-specific restriction of retroviruses, as this restriction factor does not restrict
viruses isolated from the same host species (e.g. human TRIM5α does not restrict
HIV-1). TRIMs have multiple functional domains; an N-terminal RING finger domain, one
or two B-box domains, a coiled-coil domain and many also have a C-terminal PRYSPRY
domain. This PRYSPRY domain is essential for interacting with retroviral CA proteins;
but only when the capsid is in a lattice structure [123]. The RING domain of TRIM5α
functions as an E3 ubiquitin ligase and the B-box and coiled-coil domains function
together in protein-protein interactions allowing TRIM5α to multimerize around the
retroviral CA lattice. The full nature of TRIM5α restriction is still not entirely identified, but
in its presence restricted retroviral capsid structures are prematurely disassembled and
the viral reverse transcription complex is proteasomally degraded [121]. Indeed, recently
TRIM5α was found to associate with PSMC2, a proteasomal subunit, in discrete
cytoplasmic bodies [124]. While this association occurs in the absence of restricted
virus, in its presence proteasomal association with TRIM5α cytoplasmic bodies
increased [125]. There is also evidence to suggest a non-proteasomal action of TRIM5α
in which TRIM5α blocks restricted CAs from interacting with host machinery and thereby
blocking nuclear import [126]. As the PRYSPRY domain of human TRIM5α does not
recognize HIV-1 or Moloney MLV CA proteins, it is unlikely that TRIM5α is restricting

66

transduction in the SSTR-expressing 293 cells. Although mice do not express TRIM5α,
they do have a similar host factor termed Friend virus susceptibility factor-1 (Fv1). One
of three Fv1 alleles (Fv1n, FV1b or FV1nr) are expressed by in-bred mice and they each
encode a degenerate retroviral Gag protein which binds the N-terminal domain of CA
from different MLV strains. This interaction restricts MLV infection at a point after reverse
transcription but before integration; however the action by which this occurs has not
been elucidated [127]. Neither Moloney MLV nor HIV-1 is restricted by any of the Fv1
alleles [122].
Neither the available literature nor the experimental results indicate that a host
restriction factor might be acting to reduce transduction by SSTR-2 or -3; nevertheless,
the possibility is not excluded. The issue is of particular relevance if one considers that
virions associated with SSTR-2 and -3 may not be inactivated in lysosomes as
proposed, but instead these receptors are sorted to a compartment where membrane
fusion may be just as efficient as with SSTR-5 and yet uncoating/penetration is still
somehow restricted. However, this means that the host factor must be specifically
located and accessible only by certain entry routes, blocking virions entering through
SSTR-2 and SSTR-3 but not through SSTR-5. If such a host restriction factor is involved
its identification will require further research efforts such as siRNA mediated knockdown
of the restriction factors discussed here. Transduction assays could then be performed
in the presence and absence of each respective host factor and differences in
transduction evaluated.
Targets for Sst-RBS-Mediated Gene Delivery In Vivo
SSTR-expressing Tumors
SSTRs have a broad distribution throughout the body. Surface expression of SSTRs
is abundant in the brain; gastrointestinal tract; exo- and endocrine pancreas and pituitary
[27, 28]. SSTRs have also been identified on the surface of neuroendocrine tumors
(NET) [128], breast cancer tumors [129] glial tumors and meningiomas, renal cell
carcinomas and lymphomas [130]. NETs occur most frequently in the gastrointestinal
tract (in descending order of frequency: small intestine, rectum, colon, pancreas,
stomach and appendix) but also in the bronchopulmonary system, ovaries, testes and
hepato-biliary system with much lower incidences. A majority (70-90%) of NETs express
multiple SSTRs with SSTR-2 and SSTR-5 subtypes being the most common [128].
Similarly, SSTR-2 expression is predominant in breast tumors, however, multiple SSTR
subtypes are also displayed [129]. Radio- and generator-derived positron emitter-labeled
somatostatin analogs (SSA) allow visualization of tumor lesions with nuclear imaging
techniques for diagnosis, tumor localization and grading [128]. SSAs themselves have
also been used for a variety of treatment outcomes. They have been shown to control
tumor growth, inhibit the secretion of hormones and growth factors, control
hormone-related symptoms and in some cases cause tumor shrinkage [131].
Additionally, cytotoxic drugs (such as camptothecin, methotrexate, paclitaxel, and
doxorubicin) conjugated to SSTR-2 specific analogs show positive treatment outcomes
[132] and Octreotide induced SSTR-2 internalization in NETs has been directly
demonstrated [133]. However, decreased expression of SSTRs in dedifferentiated
tumors associated with metastatic states of both NETs and breast cancers have been
documented [128, 129]. Additionally, target receptor signaling and internalization
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pathways may become interrupted in tumor cells [134] suggesting that SSA-related
diagnosis and treatment has a limited window of efficacy and early diagnosis of patients
is critical. The addition of Sst-RBS vector treatments transducing any number of
chemotherapeutic or cytotoxic genes as well as genes rendering tumors susceptible to
immune clearance may provide another valuable treatment option to clinicians. This
might prove especially attractive if gene transduction and stable expression occurs
before tumors begin downregulating SSTRs.
Central Nervous System
In chapter 5, I demonstrated proof of principle for Sst-RBS LV transduction in the
murine brain and showed that SSTR-2 is expressed in several regions of therapeutic
interest (Figures 5-1 and 5-2). Treatment of neurodegenerative diseases has been
complicated. Large complexes cannot cross the BBB and most only mask symptoms
without addressing disease progression or curative treatment. Promising advancements
have been made in response to this need, however, and I will discuss several that could
be compatible with Sst-RBS pseudotyped viral vectors.
Neurotrophic factors (NTF) are small (less than 20 kD) secreted proteins that
regulate neuronal development and maintenance. They include nerve growth factor,
brain-derived neurotrophic factor, neurotrophin-3 and 4/5, glial cell line-derived factor,
and neurturin. NTFs have been shown to slow or even prevent neurological disease by
increasing neuronal metabolism and growth and preventing death from nerve injuries
and brain traumas. They have been investigated as treatments for multiple conditions
involving neuronal destruction such as AD, HD and PD, as well as amyotrophic lateral
sclerosis (ALS), epilepsy, spinal cord injury, neuropathic pain and stroke. Several clinical
trials using AAV2 and LV vectors to transduce various NTFs for AD and PD treatment
are underway [135].
RNA interference (RNAi) strategies are another promising avenue for treatment of
neurodegenerative diseases and cancer. In vitro and preclinical models have revealed
potential therapeutic targets for ALS, AD, HD, PD and frontotemporal dementia among
others by selectively targeting mutant genes associated with these conditions. RNAi
targets for cancer treatments might include selectively targeted oncogenes or genes that
are involved in radio- or chemotherapy resistance mechanisms. As with all other
treatment strategies, technical barriers such as specific delivery of therapeutic doses to
target cells, long-term expression and the inability to cross the BBB are among the most
significant challenges, but AAV and LV vectors are capable of transducing small
interfering RNA (siRNA) and short hairpin RNA (shRNA) [136].
Viral vectors to deliver lysosomal enzyme genes such as GUSB have been
developed for mouse and dog models [137-139] and successful transduction of GUSB in
the murine brain has been documented using several types of viral vectors by both
intracranial and intraventricular routes of administration. AAV2 injected into the lateral
ventricles of an adult mouse brain had limited affect as it was only capable of accessing
the subarachnoid space and transducing pia-arachnoid and hypothalamus cells [104].
Injecting neonatal mice, however, allowed both AAV1 and AAV2 greater access to the
developing brain and nearly all brain structures were transduced with expression of
GUSB mRNA lasting for up to year in most cases. Limited transduction, mostly choroid
plexus and ependymal cells, was seen in AAV5 infected neonatal mice. Neither AAV1
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nor AAV2 transduced any glial or oligodendrocyte cells; but instead, AAV-marker
expressing cells strictly colocalized with a neuron-specific marker. Remarkably, direct
transduction was not required for protection, as demonstrated by the absence of lesions
in non-transduced glial and gray matter cells indicating that GUSB had been secreted by
transduced cells and absorbed by neighboring cells [91]. When a VSV G-pseudotyped,
HIV-based LV transducing human GUSB was injected into the striatum of adult MPS VII
mice, GUSB activity was present at injection sites and stable for up to 16 weeks.
Correction of lysosomal storage lesions was observed in areas showing GUSB activity
that could be attributed to direct and indirect viral transduction. As in the AAV vector
studies, improvement was most pronounced in neurons [90]. The most profound report
of lysosomal lesion correction, however, followed injection of a VSV G LV GUSB vector
into the lateral ventricles of 6 week old mice. GUSB activity and the presence of
lysosomal lesions were assayed after 7 months. The authors documented nearly
complete correction of lesions in all brain sections even though GUSB enzyme activity
was only significantly detected in one section [140]. These results were presumably due
to vector delivery into the CSF which was more capable of effective distribution, as
evidenced by RT-PCR detection of vector in each section. However, this may also
represent a greater capacity for distribution of secreted enzyme by the CSF originating
from transduced cells surrounding the ventricular spaces. In either case, delivery to the
CSF and its associated structures could provide an excellent target for Sst-RBS
pseudotyped viral vectors.
The choroid plexus (ChP) is an interesting structure located within the ventricular
spaces of the brain. It is composed of specialized epithelial cells that are folded into villi
surrounding fenestrated capillaries that project out into the ventricles. These frond-like
processes filter water and actively transport ions and macromolecules from blood
plasma to produce CSF. The ChP is responsible for producing, circulating and filtering
toxic substances from the CSF and brain and proteins expressed by the ChP are
excreted into the CSF [141, 142]. The ChP forms a continuous structure with the
ependymal cell layer. Ependymal cells are of a glial cell lineage. Structurally similar to
cuboidal epithelium cells (they are not true epithelial cells since they do not possess a
basement membrane or tight junctions), they line the ventricular spaces of the brain and
central canal of the spinal cord [143]. Their apical surfaces are covered in cilia and
microvilli which circulate and absorb CSF. Since the ependymal layer does not contain
tight junctions like the ChP epithelium, CSF and solutes are capable of diffusing through
this Brain-CSF interface while the ChP epithelial cells maintain the strict BBB [141].
Ependymal cells may also serve as a source of neuronal stem cells (NSC) after injury
[144]. Adult mouse ependymal cells stain positively for all SSTR subtypes, albeit at
varying intensities and locations [89]. Additionally, I demonstrated SSTR-2 expression
(Figure 5-4) and transduction by Sst-RBS LV (Figure 5-5). Human ChP epithelial cells
also stain positively for SSTR-1 and -2 [145]. Thus, the ChP and ependymal cells are
good candidates for Sst-RBS LVs transducing lysosomal enzymes and NTFs since they
interact directly with CSF which could deliver these secreted proteins throughout the
entire brain.
Other targets for CNS delivery are neurogenic regions that contain NSCs capable of
giving rise to new neurons and glial cells. If NSCs or another progenitor cell could be
transduced this would provide a source of new neurons that now express the target
gene. The subventricular zone (SVZ), which is located along the lateral walls of the
lateral ventricles, and the subgranular zone (SGZ) of the hippocampal dentate gyrus are
the two known neurogenic regions in the adult mammalian brain. The human SVZ is
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composed of four distinct layers: a single layer of ependymal cells lining the ventricle, a
gap into which the basal projections of the ependymal cells interact with astrocyte
processes, a layer of astrocyte cell bodies, and finally a transitional zone to the brain
parenchyma. The SVZ of rodents, dogs and other primates is organized differently in
that it lacks the hypocellular gap layer separating the ependymal cells from astrocytes
(which can be subdivided into B1 and B2 cells) and contains many more rapidly dividing
immature precursor cells (termed C cells) and migrating neuroblasts (termed A cells)
[94, 146, 147]. The SVZ’s location and cellular population create a “germinal niche”
providing the vasculature and important cellular signals that support neurogenesis [144,
148]. The primary progenitor NSCs of the SVZ have been identified as the B1 population
of astrocyte cells [146]. These GFAP positive cells are derived from the same radial glial
lineage as ependymal cells [143, 149] and remain in close association with them in the
SVZ, projecting processes between the ependymal cells and directly contacting the CSF
of the lateral ventricles forming a “pinwheel” of ependymal cells surrounding the
astrocyte processes [148, 150]. The B1 cells receive neurogenic signals from the
components of the germinal niche stimulating them to develop into the transient
amplifying C cells which then become immature neuroblasts [144, 148, 151]. In the
rodent SVZ the neuroblasts are supported by the glial sheaths of the B2-type astroctyes
and form long chains that migrate along the rostral migratory stream (RMS) to the
olfactory bulb where they finally mature [144]. While NSCs have been isolated from the
adult human SVZ, the existence of the RMS to olfactory bulb pathway has been a
source of debate. Recently, however, it was discovered that migrating neuroblasts are
found along the RMS; but as single or double cells, not in long chains as in the rodent
RMS [152]. Aside from ependymal cells, the expression of SSTRs on other SVZ cell
types has not been documented. If they do express SSTRs this neurogenic region
presents an intriguing target cell population. Because they migrate long distances from
their location of genesis (and possibly transduction) they have an opportunity to deliver
secreted proteins not only at their final destination but along the RMS as well.
The second area of neurogenesis in the adult brain is the SGZ. In this region of the
hippocampus, radial glial-like precursors first develop into neuronal progenitor cells and
then neuroblasts which migrate throughout the granular layer of the dentate gyrus. To
become mature granular cells the new neurons extend dendrites towards the molecular
layer and project axons through the hilus into the CA3 region of the hippocampus. The
dentate gyrus is strongly positive for SSTR-2 expression (Figure 5-2B) and SSTR-1 and
SSTR-2 are also expressed in the CA3 region [153]. As the hippocampus is one of the
first regions showing neurodegenerative damage in AD [154], these regions could be
excellent candidates for Sst-RBS targeted viral vectors transducing NTFs.
Conclusion
I demonstrated that a modified MLV glycoprotein, Sst-RBS, has a transduction
capacity comparable to that of the WT MLV Env and approaches that of VSV G, the
“gold standard” in transduction efficiency in in vitro transduction assays (Figures 3-1 and
4-2). I observed that only one Sst-RBS target receptor subtype, SSTR-5, was capable of
reaching this level of transduction, evidently because other receptors tested delivered
virions to degradative environments (Figures 4-9 and 4-10) that were less permissive for
entry; whereas SSTR-5 associated virions were directed to more permissive
compartments that allowed efficient cytosolic penetration (Figure 4-11). Yet, in vivo
transduction assays carried out in the murine brain did not seem to correlate with the in
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vitro data as transduction of both Sst-RBS and VSV G pseudotyped LV vectors was
similar (Figures 5-6 and 5-7).
During the course of investigating the transduction capacity of Sst-RBS and its
potential for use as an in vitro gene delivery vector, the area of vector diffusion was
measured for Sst-RBS and VSV G Envs. Interestingly, Sst-RBS showed a greater
potential for vector diffusion than VSV G in which transduction was generally
concentrated in a small core area (Figure 5-7). This is a significant observation because
delivering therapeutics to brain cells may be more effective if a gene can be delivered to
a larger overall area, rather than high transduction in a very small area. For example,
genes that encode secreted proteins such as deficient lysosomal enzymes or
neurotrophic factors will generate a higher level of therapeutic benefit in this situation
because a greater area is covered using fewer vectors. Additionally, since the proteins
are secreted, non-transduced cells in the transduction zone also benefit. The coding
sequences of the deficient enzymes causing lysosomal storage diseases are less than
5000 base pairs, well within the capacity limits of LV.
SSTR-2 receptor expression was observed in neurons and ependymal cells
(Figures 5-3 through 5-5) making these cells types potential targets for gene
transduction by Sst-RBS coated viral vectors. Moreover, delivery of the transduction
marker mKate2 was demonstrated in ependymal cells. Because the ependymal cells line
the ventricles of the brain, they are in close association with the CSF which provides
another intriguing delivery route. Since the CSF is naturally distributed throughout the
CNS; proteins secreted into the CSF by ependymal cells could potentially gain access all
neurological cell types. In the current study, transduction was achieved through direct
injection into the murine brain parenchyma. However, this highly invasive method of
delivery is not feasible in humans. Less invasive delivery methods exist to access the
CSF including spinal taps and intrathecal catheters making delivery to the CSF and its
associated structures (the ependymal and choroid plexus cells) an even more attractive
option.
One of the more interesting questions remaining after these studies is that of
identifying the intracellular compartments to which SSTR-2, -3 and -5 direct the Sst-RBS
virus in culture. Using DN-Rab proteins and fluorescent microscopy this information
could easily be obtained. Yet, the dramatic difference in transduction capacity between
SSTR-2 and SSTR-5 expressing cells did not translate into a similarly low transduction
capacity in vivo. This difference may actually represent a cell culture artifact and
therefore more useful information would be obtained by concentrating experimental
resources on in vivo studies. Moreover, additional information pertaining to in vivo
transduction, beyond that generated during this preliminary investigation needs to be
attained. First, the sample sizes for transduction and diffusion zone areas should be
greater so that large variations due to the nature of individual animals can mitigated.
Second, more definitive proof that transduction is SSTR specific should be obtained.
Competition assays between Sst-RBS and VSV G pseudotyped vectors in the presence
and absence of the inhibitory peptide, SST-14, may be able to answer this question.
Third, greater detail regarding the expression of other SSTR subtypes in neurological
cell types should be generated. Monoclonal antibodies specific to each of these receptor
subtypes can be obtained and immunohistochemical staining protocols similar to those
here can be used. In conclusion, demonstrating proof of principle for in vivo gene
transduction by the modified retroviral glycoprotein, Sst-RBS, is certainly an exciting
advance in the gene therapy field.
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